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ABSTRACT 
 
Large differences exist between countries in the context and use of postmenopausal hormone 
therapies. Differences also exist in genes, diet and lifestyle, which all affect the risk for 
cancers. I studied the effects of different estrogen-progestagen therapies (EPT) for the risk of 
endometrial and cervical cancer as well as uterine sarcoma in nationwide studies on 
postmenopausal Finnish women. 
 
A cohort of all Finnish women (> 50 years of age) who had used EPT for at least 6 months 
since 1994 was collected from the national Medical Reimbursement Register and followed for 
uterine cancers with the aid of the Finnish Cancer Registry. The risks were compared to those 
of the same age background population in the three cohort studies. The follow-up for the 
endometrial cohort study ended in 2006 and encountered a total of 1,364 endometrial cancer 
cases out of a total of 224,015 women with EPT. The follow-up was continued until the end 
of 2008 in the other cohort studies and accumulated 243,857 women with EPT of which 192 
women showed cervical precancerous lesions, 97 women cervical cancers and 76 women 
uterine sarcomas (45 leiomyosarcomas, 24 stromal sarcomas and 7 other sarcomas). 
 
To control some of the various confounding factors and to assess, in addition to EPT, also the 
impact of tibolone, another study using a case-control study model was conducted. In total 
7,261 women with endometrial cancer and 19,490 controls were compared in regard to the 
use of EPT or tibolone in 1995-2007. Hysterectomized women were excluded from the 
controls based on data from the Hospital Inpatient Register of the National Institute of Health 
and Welfare. Results were adjusted for parity, age at first delivery and hospital district, but 
not for body mass index, diabetes mellitus or socioeconomic status.  
 
In the cohort study, the incidence of endometrial cancer was increased among sequential EPT 
users after 5 years of use (standardized incidence ratio (SIR) 1.69; 95% confidence interval 
(CI) 1.43-1.96) when progestagen was added monthly and the risk doubled to 3.76 (2.90-4.79) 
when progestagen was added at 3-month intervals. In the case-control study, sequential EPT 
showed increased risk only after 10 years of use (odds ratio (OR) 1.38; 1.15-1.66) but long-
cycle sequential EPT associated with increased risk after 5 years of use (1.63; 1.12-2.38). The 
use of tibolone showed no effect on endometrial cancer risk, but the number of cases (n = 19) 
was small. In contrast, the use of continuous combined EPT users was accompanied with a 
reduced risk for endometrial cancer from 3 years onwards (SIR 0.24; 0.06-0.60). Similar risk 
reductions for endometrial cancer were seen also in women using continuous combined EPT 
or an estradiol plus levonorgestrel releasing intrauterine system in the case-control study; the 
odds rations were 0.57 (0.37-0.88) and 0.16 (0.37-0.68), respectively. 
 
In the cohort study, endometrial cancers of women using monthly sequential EPT tended to 
be diagnosed more often in a localized stage than endometrial cancers in general. The most 
common oral progestagens as parts of EPT in Finland (norethisterone acetate, 
medroxyprogesterone acetate and dydrogesterone) showed no significant differences in the 
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endometrial effects. Transdermal and oral routes of administration showed similar risks for 
monthly sequential EPT regimen including estradiol and norethisterone acetate.  
 
The incidence of cervical precancerous lesions in all EPT users did not differ from that in the 
background population, but the risk for squamous cell carcinoma was decreased (SIR 0.41; 
0.28-0.58) and that of adenocarcinoma was increased (1.31; 1.01-1.67). When the use of EPT 
exceeded 5 years, the risk for squamous cell carcinoma showed a trend towards a further 
decrease 0.34 (0.16-0.65), and the risk of adenocarcinoma showed a trend towards an increase 
1.83 (1.24-2.59). 
 
The risk for uterine sarcomas was not affected by the exposure to EPT for less than 5 years. 
Uses of EPT for 5-10 and 10+ years associated with an increased risk for uterine sarcomas 
(SIR 2.02; 1.36-2.91 and 3.01; 1.30-5.93); risks were highest for leiomyosarcoma. The mode 
of EPT did not affect these risks significantly.  
 
In conclusion, the use of postmenopausal EPT is one determinant for the occurrence of 
uterine cancers. Continuous combined regimens decrease and sequential regimens increase 
the risk for endometrial cancer; these data support earlier findings. The following new 
observations were made; oral and transdermal routes of administration or various types of 
progestagens do not modify these effects. A consistent decrease in the incidence of squamous 
cervical malignancies was seen in EPT users. In contrast, the incidence of cervical 
adenocarcinoma was increased. The risk for uterine sarcomas is increased if EPT has been 
used for longer times. These data are of importance for the potential users of EPT and for 
physicians prescribing such regimens. 
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INTRODUCTION 
 
The uterus is an extraordinary organ with a capacity to bear a child and to give birth. Yet, the 
uterus can also be an origin of various disorders. During the fertile years, abnormal bleedings 
and fibroids are common and often lead to hysterectomy (see, e.g., Brummer et al 2009). 
 
In postmenopausal ages, several malignancies can originate from the uterus. Of these, 
endometrial cancer is the most common, followed by cervical cancers and uterine sarcomas. 
In Finland these cancers together are second only to breast cancer (Finnish Cancer Registry 
2010). The various cells and functions of the uterus are regulated by estrogens and 
progestagens which derive from the ovaries (Yeh 2007, Chen et al 2008). The uterus also 
becomes exposed to exogenous hormones such as of contraceptive pills during the fertile 
years and hormonal therapy (HT) after menopause. 
 
Postmenopausal HT is commonly used in the Western world to control menopausal 
vasomotor and vaginal symptoms. The leading organisations recommend using HT at the 
smallest possible doses and for the shortest possible durations (Finnish Consensus Statement 
2004, International Menopause Society 2007, and North American Menopause Society 2010). 
In Finland the use of HT is popular; over 40% of postmenopausal use it at least 6 months 
(Lyytinen et al 2009). While HT undoubtedly improves the quality of life, it is not harmless. 
Hormone therapies increase the risk for venous thromboembolism and the risk for breast 
cancer (Lyytinen 2009). Estrogen causes endometrial hyperplasia and increases the risk for 
endometrial cancer (Judd et al 1996, Santen et al 2010), and this risk may not be fully 
eliminated by the addition of progestagen to estrogen (Weiderpass et al 1999, Bjarnason et al 
1999, Pukkala et al 2000, Doherty et al 2007). 
 
The International Agency of Research on Cancer has classified combined estrogen-
progestagen menopausal therapy as a carcinogenic agent (International Agency for Research 
on Cancer 2007). Hormone therapies used around the world differ with regard to the contents 
(estrogens/progestagens), modes of regimen (sequential/continuous) or routes of 
administration (oral/transdermal/intrauterine), and therefore risk analysis from one country 
may not be applicable to another (Cogliano et al 2005). It is also noteworthy that genes, 
nutrition and lifestyles affect the general risk for cancers, and uterine malignancies may not be 
an exception to this rule. All this inspired me to study associations of different 
postmenopausal hormone therapies and uterine cancers among Finnish postmenopausal 
women.  
11 
 
REVIEW OF THE LITERATURE 
 
Uterus 
 
The uterus consists of myometrium, the endometrium and the cervix (Figure 1). Myometrium, 
composed of smooth muscle cells, has a great ability to expand in size by both cell division 
(hyperplasia) and cell growth (hypertophy), e.g., during pregnancy the uterine weight rises 
10-fold. The mucosal lining inside the uterus is called the endometrium and it provides the 
environment for pregnancy. The endometrium is linked to the cervix that protrudes into the 
upper vagina. The cervical canal is lined with a single layer of columnar mucus-secreting cells 
except for the part that extends to vagina, where it is lined with squamous epithelium 
(Wheather’s Functional Histology 1993). At the squamocolumnar junction, the vaginal and 
endocervical epithelium meet. 
 
The endometrium is governed by ovarian estrogen and progesterone secretion, which causes 
proliferation and secretion phases in the endometrium. 17β-estradiol is the predominant 
endogenous estrogen in circulation before menopause. Estrone is formed in adipose tissue 
through oxidation from adrenal androstenedione, and it is found in the highest concentrations 
after menopause. Both estradiol and estrone are converted to estriol in the liver, and estriol, 
the main metabolite of estrogens, shows a weak estrogenic activity. However, during 
pregnancy, estriol is produced in high amounts in the placenta and fetoplacental unit (Files et 
al 2011). 
 
Figure 1. Illustration of human uterus. 
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Endocrine aspects of carcinogenesis 
 
Uterine malignancies can occur in the endometrium, cervix or myometrium. Most of the 
uterine cancers express receptors for sex steroids, and therefore the genesis of these 
malignancies may be influenced by postmenopausal hormone therapy (Tinelli et al 2008, 
Ioffe et al 2009, Chung et al 2010). Two forms of estrogen receptors (ER), ERα and ERβ are 
present in the healthy and malignant uterine tissue. The carcinogenetic effects of estrogens 
may be either adverse or beneficial and depend on cell or organ types (Chen et al 2008). 
Progesterone receptors (PR) also express in two isoforms (PRA and PRB) in various uterine 
malignancies. It has been speculated that individual variation in these receptors may be one 
determinant for the development and behaviour of different cancers (Ito et al 2007). In 
general, the presence of steroid receptors in malignancies is a sign of high differentiation (Prat 
2004). 
 
Endogenous hormones, especially estrogen, and growth factors affect carcinogenesis by 
regulating the balance between cell proliferation, differentiation, and apoptosis (Kaaks et al 
2004). Increased cell proliferation enhances the probability for the accumulation of gene 
mutations of oncogenes and tumor suppressors. The higher is the cell differentiation, the 
smaller is the risk for malignancy. The cells are genetically programmed to die in a given age 
through apoptosis and suppressed apoptosis may result the survival of cells with detrimental 
gene mutations (Kaaks et al 2004). 
 
The most common reasons for endogenous estrogen excess in females are polycystic ovarian 
syndrome and obesity. The level of insulin increases with increasing body mass index (BMI), 
but at the same time peripheral tissue becomes resistant to insulin. These result in 
hyperinsulinism, decreased levels of insulin-like growth factor binding proteins (IGFBP) and 
elevated levels of free insulin-like growth factors (IGF). Chronic hyperinsulinemia and a high 
concentration of free IGF-1 inhibit the hepatic synthesis of sex-hormone binding globulin, 
and the levels of biologically active free androgens and estrogens rise. The level of estrogens 
is also increased through aromatization of androstenedione to estrone in adipose tissue (Calle 
and Thun 2002). In polycystic ovarian syndrome, levels of testosterone and the luteinizing 
hormone in plasma are increased. Ovarian hyperandrogenism inhibits ovulation and chronic 
progesterone deficiency ensues. This is accompanied with decreased level of IGFBPs but 
increased level of IGF-1. Both bioactive estrogen and IGF-1 stimulate cell proliferation, 
inhibit apoptosis, and may thus reduce cell differentiation and promote angiogenesis. All 
these effects increase the risk of carcinogenesis also in various uterine cells (Kaaks et al 2004, 
Amant et al 2005). In this system progesterone acts as a natural antagonist to estrogen and 
may reduce the risk of malignant transformation especially in endometrial cells (see for a 
review Rutanen 2000). 
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Endometrial cancer 
 
Endometrial cancers can be divided into two major subdivisions; type I, endometrioid 
endometrial adenocarcinoma, which is well-moderately differentiated and dependent on 
estrogen, whereas type II, non-endometrioid endometrial carcinoma is less differentiated, 
more aggressive and not dependent on estrogen (Table 1) (see for reviews Amant et al 2005, 
Acharya et al 2005, Brown 2008). 
 
About 80-90% of all endometrial cancers belong to type I endometrioid carcinomas. This 
cancer typically occurs in peri- or postmenopausal women. The association of estrogen and 
the risk for endometrial cancer was first noticed among patients with estrogen secreting 
ovarian granulosa cell tumors (see for a review Creasman 2002). Hyperestrogenism causes 
endometrial hyperplasia: simplex (cystic glandular) or complex (adenomatous) which may 
also present atypical cytological changes. Of these hyperplasia forms, approximately 5% of 
nonatypical hyperplasia will progress to endometrial cancer in 20 years (Lacey et al 2010). 
However, the risk for atypical complex hyperplasia progressing to endometrial cancer is 
markedly higher, approximately 50% (Horn et al 2004, Brown 2008). Endometrial 
hyperplasia and endometrial cancer express themselves with bleeding and as thickening of the 
endometrium, and histological sampling is the only method to distinguish cancer from 
hyperplasia.  
 
 
Table 1. Principal forms of endometrial cancers (modified from Acharya et al 2005). 
 Type I Type II 
Incidence/100,000 person years1 14 0.2 
Menopausal status Pre- and perimenopausal Postmenopausal 
Pathogenesis Microsatellite instability, 
mutations in KRAS 2 
oncogene and PTEN tumor 
suppressor gene 
Mutations in p53, 
overexpression of ERBB2  
Estrogen or progesterone receptors +++ +/- 
Estrogen dependence Strong Vague 
Histological characteristics Atypical hyperplasia Atrophy 
Histological type Endometrioid Papillary serous 
5-year overall survival (%) 
 FIGO2 Stage I 
                      II 
                      III 
                     IV 
83 
90 
80 
68 
26 
53 
80 
40 
38 
0 
1Adjusted for age to the world standard population (A rate is the number of new cases or deaths per 100 000 persons per 
year. An age−standardized rate is the rate that a population would have if it had a standard age structure. Standardization is 
necessary when comparing several populations that differ with respect to age because age has such a powerful influence on 
the risk of cancer.)  
2International Federation of Gynecology and Obstetrics 
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Type II endometrial carcinomas include uterine papillary serous carcinoma, clear cell 
carcinoma, mixed tumors with undifferentiated histology, mucinous tumors and squamous-
cell carcinomas (Acharya et al 2005). It is also noteworthy that approximately 40% of non-
endometrioid cancers are mixed with an endometrioid endometrial cancer (Amant et al 2005). 
Type II cancers account for approximately 10% of all endometrial cancers, but their clinical 
burden is heavy due to the high rate of relapse (50%). At the time of diagnosis, a majority of 
papillary serous carcinomas are spread out of the uterus (69-87%) and the 5-year overall 
survival is poor (Acharya et al 2005). The most important prognostic factors for endometrial 
cancer are differentiation grade, histological type, myometrial invasion and stage of disease 
(Amant et al 2005, Creasman et al 2006). In Finland, the 5-year relative survival rate for all 
endometrium cancer (including both cancer types) has risen from 60% to 83% since 1960’s 
(Engholm et al 2011). 
 
Incidence 
 
Worldwide, endometrial cancer is the sixth commonest cancer in women, but in Finland it is 
the third commonest cancer after breast and colon cancers (Jemal et al 2011, 
www.cancerregistry.fi). The incidence is ten times higher in the United States and Europe 
than in developing countries. In Finland, approximately 800 new cases of endometrial cancer 
are detected annually, and it is the commonest uterine malignancy. The risk for a 50-year old 
woman to get endometrial cancer is 2.4% in her remaining life time. It has been predicted that 
the incidence of endometrial cancer will increase by 29% to the year 2020 (Figure 2) 
(www.cancerregistry.fi).  
 
Figure 2. Incidence and mortality of endometrial cancer (type I and II combined) by age 
in Finland 1994-2006 (Engholm et al 2011). 
 
Incidence 
Mortality 
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Diagnosis 
 
The most frequent symptom of endometrial cancer is intermittent and/or heavy bleeding 
among perimenopausal women. In postmenopausal women, any bleeding is a sign for 
possible endometrial malignancy. An early sign is also a thickened endometrium (> 5 mm), 
which can be detected with a vaginal ultrasound examination (van de Weier et al 2006). 
Endometrial biopsy is the cornerstone of the diagnosis, since it shows a high sensitivity (81-
99%) and specificity (98%) for atypical endometrial hyperplasia and endometrial cancer 
(Amant et al 2005). The Pap smear or endometrial brushes find only approximately 30% 
endometrial cancer cases. Organized screening of the endometrium for endometrial cancer 
with ultrasound may detect new cases, but due to the high number of false positive findings, 
such screenings are not cost-effective and do not reduce mortality for this cancer, and 
therefore mass screenings are not conducted presently in any country (Amant et al 2005). 
 
Risk factors 
 
Type I endometrioid endometrial carcinomas are estrogen related, and therefore, “high” 
estrogenic states like obesity, nulliparity, and long period from menarche to menopause 
increase the risk (Kaaks et al 2002, Amant et al 2005) (Table 2). Stimulation by endogenous 
or exogenous estrogen alone may not be enough to induce carcinogenesis, but proliferative 
activity induced by estrogen increases the risk for errors in transcription (microsatellite 
instability, K-ras mutation, PTEN gene mutations), which are essential for carcinogenesis 
(Yeh 2007). Estrogen may operate through “classical” genomic pathways (via nuclear ERs) or 
non-genomic pathways (ERs in plasma membrane/cytoplasm or other receptors/adaptors) 
(Chen et al 2008). Approximately 10% of the patients with endometrial cancer show gene 
defects promoting the carcinogenesis; one representative example is hereditary non-polyposis 
colon cancer (HNPCC) syndrome, when the lifetime risk for endometrial cancer is 40-60 % 
(Tinelli et al 2008, Brown et al 2012). In addition, being Caucasian, infertility, the polycystic 
ovary syndrome, estrogen producing tumors, history of breast cancer or tamoxifen use and  
 
Table 2. Risk factors for endometrial cancer (modified from Amant et al 2005).  
Factors increasing risk Factors decreasing risk 
Advanced age Multiparity 
Caucasian race Advanced age at last delivery 
Obesity  Smoking 
Diabetes Oral contraceptive use 
Several years with menstrual cycle  Physical activity 
Nulliparity  
History of breast cancer  
Long term use of tamoxifen  
Hereditary non-polyposis colon cancer 
syndrome 
 
First degree relative with endometrial cancer  
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first degree relatives with endometrial cancer, increase the risk for type I cancer (La Veccia et 
al 2002, Amant et al 2005). In contrast, the long-term use of oral contraceptives is associated 
with an 80% reduction in the risk for endometrial cancer (Kiley and Hammond 2007); 
multiparity is also associated with a reduced risk (Hinkula et al 2002). For type II non-
endometrioid endometrial carcinoma, only advanced age is an established risk factor, and 
obesity may be another (Bjorge et al 2007, Mc Cullough et al 2008). The role of 
postmenopausal hormone therapy (HT) as a risk factor for this cancer will be discussed later 
in this theses (page 29).  
 
Uterine sarcoma 
 
Uterine sarcomas which contribute 3-4% of all uterine malignancies include a heterogeneous 
group of mesenchymal tumors. They are usually classified into those that arise from smooth 
muscle cells of the myometrium or from endometrial stroma (Acharya et al 2005). In the new 
classification of International Federation of Gynecology and Obstetrics, carcinosarcoma is 
classified as metaplastic/dedifferentiated form of endometrial carcinoma. Currently, 
leiomyosarcoma is the most frequent (approximately 60%) followed with endometrial stromal 
sarcoma (approximately 30%) (Table 3). Mixed tumors with benign epithelial and malignant 
stromal sarcoma components are classified as adenosarcomas, and they are less malignant 
forms of all sarcomas considered (see for reviews Acharya et al 2005, Amant et al 2009, 
D’Angelo and Pratt 2010, Garcia-Martínez et al 2011). 
 
Leiomyosarcoma with rare variants (epitheliaoid and myxoid) arise from the smooth muscle 
cells of myometrium and they account for 1-2% of all uterine malignancies. The median age 
for leiomyosarcoma patients was 55 in the Finnish (Koivisto-Korander et al 2010) and 56 
years in the Norwegian study (Abeler et al 2009). Leiomyosarcoma may manifest itself with 
abnormal uterine bleeding (56%), palpable pelvic mass (54%) and pelvic pain (22%). These 
clinical features resemble those of benign leiomyoma, but a rapid growth, large size (>10 cm), 
extrauterine extension, peri-postmenopausal age and tumor necrosis may imply for 
leiomyosarcoma (D’Angelo and Pratt 2010). Leiomyosarcoma coexists frequently with 
leiomyomas, but only 0.5% of preoperatively assessed leiomyomas have been proven to be 
leiomyosarcomas  after hysterectomy (Acharya et al 2005).  
 
Hormone receptors are often present in uterine leiomyosarcomas; 50-60% of them express 
receptors for estrogen and 17-60% for progesterone (Table 3) (Leitao et al 2004, Gaducci et al 
2008). The high content of progesterone receptors may hint at the borderline tumors in the 
differential diagnosis between semi- and true malignancies (Bodner et al 2004). High content 
of ER or PR (>10%) in leiomyosarcoma cells predict better disease-specific survival (Akhan 
et al 2005, Koivisto-Korander et al 2010). Hormonal treatments such as progestagen receptor 
antagonist, aromatase inhibitor and medroxyprogesterone acetate (MPA) have been used for 
treatment of advanced leiomyosarcoma with varying success (Koivisto-Korander et al 2007, 
Hardman et al 2007, Martínez et al 2011, Ioffe et al 2009). The five-year survival rate of  
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Table 3. Main features for different types of uterine sarcoma. 
 Leiomyosarcoma Endometrial stromal sarcoma 
Incidence/100,000 person-years1 0.33 0.21 
Proportion (%) 60 30 
Median age of the women 56 51 
Estrogen receptors (%) 50-60 71 
Progesterone receptors (%) 17-60 95 
5-year overall survival (%) 
            Localized stage 
            Advanced stage 
57 
50-60 
0-25 
65 
84 
50 
1Adjusted for age to the world standard population 
 
 
leiomyosarcoma patients ranges from 50-65%. The mitotic index, tumor size and grade, and 
stage of disease serve as prognostic markers (Acharya et al 2005, D’Angelo and Pratt 2010). 
 
Low-grade endometrial stromal sarcoma accounts about 80% of stromal neoplasms (Chu et al 
2002), but only approximately 0.2% of all malignant uterine tumors (D’Angelo and Pratt 
2010). By definition, low-grade endometrial stromal sarcomas compose exclusively of cells 
resembling the endometrial stroma at its proliferative phase. Without this evidence, 
endometrial sarcomas are classified as poorly differentiated/undifferentiated uterine sarcomas 
(former high-grade) (Amant et al 2009). This sarcoma was diagnosed with a median age of 52 
in the Finnish (Koivisto-Korander et al 2008) and 51 in the Norwegian study (Abeler et al 
2009). Symptoms such as abnormal uterine bleeding, pelvic pain and dysmenorrea are similar 
to those of other uterine sarcomas; but 25% of patients are asymptomatic (D’Angelo and Pratt 
2010). This sarcoma type is characterized by recurrence after many years; most commonly in 
the pelvis and abdomen, but also metastases in the lungs and vagina may be seen.  
 
Endometrial stromal sarcoma is hormone-sensitive; most cases of low-grade tumors present 
estrogen and progesterone receptors (71% and 95%, respectively) (Reich et al 1999). Estrogen 
has been shown to stimulate these tumors, therefore at hysterectomy, ovariectomy is 
recommended; with the exception of young women with localized disease. Progestagen, 
aromatase inhibitors and gonadotropin releasing hormone analogues have been effective, and 
they are recommended for advanced cases (Pink et al 2006, Garcia-Martínez et al 2011).  
 
Incidence 
 
Incidence for uterine sarcoma varies 0.9 to 4.7/100,000 for women in the US (O’Meara 2004). 
These tumors are twice more common among black than white women (Brooks et al 2004). In 
Finland, approximately 30 women are diagnosed with uterine sarcomas each year, and this 
results the incidence of 0.71/100,000 women in 2008 (www.cancerregistry.fi).  
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Diagnosis 
 
The first clinical finding for leiomyosarcoma is an enlarged, hard uterus that can be palpated 
at pelvic examinantion. An ultrasonography or magnetic resonance imagination may give 
stronger hints at uterine leiomyosarcomas; typical findings are large, oval shaped tumors with 
mixed or poor echogenic parts, central necrosis and absence of calcifications. However, these 
techniques may fail in the diagnosis, which ultimately is made on histological examination 
(Amant et al 2009). Leiomyosarcomas show hypercellularity, severe nuclear atypia, high 
mitotic rate (≥10-15 mitotic figures/ 10 high-power-fields), infiltrated borders, necrosis and 
vascular invasions (Acharya et al 2005, Gaducci et al 2008, D’Angelo and Pratt 2010). 
  
Endometrial stromal sarcomas can be seen on an ultrasonography as a hypoechogenic mass 
with irregular margins, and the tumor may involve both endometrium and myometrium 
(Amant et al 2009, D’Angelo and Pratt 2010). A similar finding is encountered in a magnetic 
resonance, which may also reveal tumor growth along blood vessels and uterine ligaments. 
Neither of these imagination examinations is specific for the endometrial stromal sarcomas 
(Amant et al 2009). It is also noteworthy that endometrial biopsy is diagnostic only for 64 % 
of sarcoma cases (Bansal et al 2008). The final diagnosis is based on histological microscopy 
examination, immunohistochemistry and molecule biological analyses (D’Angelo and Pratt 
2010).  
 
Risk factors 
 
The aetiology of uterine sarcomas is unknown, but risk factors are similar to those for 
endometrial cancer: obesity, advanced age and nulliparity (O’Meara 2004). Menarche before 
13 years of age doubles the risk for leiomyosarcoma in comparison with women whose 
menarche occurred after the age of 13; such a relation is not seen for other sarcoma types 
(Schwartz et al 1991). In the case-control study, weight ≥ 27.5 kg/m2 was associated with a 
2.5-fold risk for leiomyosarcoma and a 3.5-fold risk for endometrial stromal sarcoma. In the 
same study on 167 uterine sarcoma patients, long term use of oral contraceptives was 
associated with a 1.7-fold risk for leiomyosarcoma (Schwartz et al 1995). The role of 
postmenopausal HT on the risk for uterine sarcomas will be discussed later (page 34). 
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Cervical cancer 
 
Screening and Diagnosis  
 
The screening of cervical cancer is based on Pap smears which are interpreted with 
Papanicolaou or the Bethesda System 2001 (TBS 2001) (Solomon et al 2002). The final 
diagnosis is made of histological samples (punch biopsies) taken at colposcopy. There exist 
various classifications for the cytological and histological findings of cervical lesions and they 
have been adapted differently in various countries (Table 4). Indications for colposcopy are 
macroscopically suspicion of cervical or vulva cancer, atypical cellular changes in the smear, 
indefinite bleeding or when prolonged vulvas or vaginal irritation occurs. Cytological 
indications for colposcopy are given in Finnish Current Care guidelines 2010. All women 
with a cervical intraepithelial neoplasia (CIN) grade 3 lesion or invasive cancer cases must be 
reported to the Finnish Cancer registry. 
 
Since 1960, the Finnish mass screening system has offered a free of charge Pap smear for 
women aged from 30 to 60 at 5 year intervals. Pap smears are also often taken at visits to 
gynecologists. Starting screening at younger age and its continuation after 60 years have been 
discussed (Finnish Cancer Registry 2009, Yasmeen et al 2006), but the Ministry of Social 
Affairs and Health has decided not to change the age limits at least before 2014. The Pap 
smear is much more sensitive to detect squamous cell changes than changes in glandular cells 
(Gunnell et al 2007, Sasieni et al 2009), even though mass screening has resulted in the 
reduction of the incidence of both cancers (Nieminen et al 1995, Bray et al 2005). Screening 
for high risk human papillomavirus (hrHPV) with smear is more accurate than a conventional 
Pap smear in the detection of cervical lesions and therefore, replacement of conventional Pap 
screening by combining hrHPV testing has been advocated (Anttila et al 2010, Schiffman et 
al 2011). This issue has been also discussed in Finland and a new organized screening scheme 
including hrHPV detection is under consideration at Ministry of Social Affairs and Health. 
 
 
Table 4. Correspondence of cytological and histological classifications in dysplasia level 
of squamous cell lesions. 
Cytology    
 Papanicolaou II-III III III-IV 
 TBS 2001 LSIL ASC-H, HSIL HSIL 
Histology    
 CIN CIN 1 CIN 2 CIN 3 
 Dysplasia Mild  Moderate  Severe  
TBS 2001 = the Bethesda System 2001; CIN = cervical intraepithelial neoplasia; LSIL = low-grade squamous 
intraepithelial, HSIL = high-grade squamous intraepithelial lesion; ASC-H = atypical squamous cells, HSIL not 
excluded. 
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The vast majority of cervical malignancies consist of squamous cell carcinoma (Table 5). It is 
developed through CIN lesions that can persist, progress and regress, and various factors, 
such as the age of the patient, histological differentiation of the CIN lesion, or capacity of the 
immune defence may determine the final outcome of the CIN lesion (Schiffman et al 2011, 
International Agency for Research on Cancer 2005, Rahkola-Soisalo 2011). The development 
from CIN grade 3 to invasive cancer is thought to be slow, but little is known about the 
factors that cause the invasions of the cancer cells through the epithelial basement membrane 
(Schiffman et al 2011). Therefore CIN grade 3 lesions are treated without delay. The depth of 
the stromal invasion, tumor size and lymph vascular invasion are the most reliable prognostic 
markers for cervical cancer (Table 5) (Singh and Arif 2004, Quinn et al 2006). 
 
Cervical adenocarcinoma, which arises from the mucus-secreting columnar epithelium lining 
endocervical canal, may be preceded by adenocarcinoma in situ -form (AIS). 
Adenocarcinomas are divided to several histological subtypes (,e.g., endometrioid, clear cell, 
mucinous endocervical), and they may express with or without AIS; CIN lesions may also be 
present. These tumors or their skip-lesions may also originate higher in the endocervical 
canal, where they are not seen by a colposcopy (Wang et al 2006). This emphasizes the need 
for a careful intracervical sampling both for cytological and histological examination.  
 
 
Table 5. Principal features of cervical cancer. 
 Squamous cell carcinoma Adenocarcinoma 
Incidence/100,000 women-years1 2.5 1.3 
Human papillomavirus16/18 (%) 70 35-50 
Precursor Cervical intraepithelial 
neoplasia 
Adenocarcinoma in situ 
Estrogen receptors (%) 41 39 
Progesterone receptors (%) 30 33 
5-year overall survival (%) 
FIGO2 Stage I 
                      II 
                      III 
                      IV 
71 
91 
71 
42 
16 
69 
85 
61 
32 
15 
1Adjusted for age to the world standard population 
2International Federation of Gynecology and Obstetrics 
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Incidence 
 
Globally, cervical cancer is the third most common female malignancy (Jeman et al 2011), 
and approximately 80% of the cases occur in developing countries (Schiffman et al 2007). In 
Finland, approximately 600 women are diagnosed with precancerous lesions and 150 women 
with cervical cancers each year (Figure 3). Of the cervical cancers, squamous cell carcinoma 
accounts for 60%, adenocarcinomas 26% and other/unknown morphology 14% (Table 6) 
(Finnish Cancer Registry 2011). The incidence of squamous cell carcinoma was 2.5/100,000 
women-years and that of adenocarcinoma 1.3/100,000 women-years, adjusted for age of 
World Standard Population in Finland 2008.  
 
The incidence of cervical cancer has decreased in Finland, except in age groups from 30 to 39 
years, since the 1990s (Finnish Cancer Registry 2009). The cause of this phenomenon is 
unclear, but a low attendance for screening in this age group is one possible explanation.  
 
 
Figure 3. Incidence and mortality of uterine cervical cancer 1994-2008 by age in Finland 
(Engholm et al 2011). 
 
Incidence 
Mortality 
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Table 6. Number of new cervical premalignant and malignant cases in Finland in 5-year 
periods 1984-2008. 
 1984-1988 1989-1993 1994-1998 1999-2003 2004-2008 
Cervical intraepithelial 
neoplasia 
1166 1913 2940 3985 3733 
Adenocarcinoma in situ 9 10 55 127 225 
Squamous cell carcinoma 594 484 550 516 464 
Adenocarcinoma 145 184 229 228 236 
 
 
Squamous cell carcinoma in Finland occurs 2-3 times more often in the lowest social class 
compared to the highest one but for the occurrence of adenocarcinoma social class has no 
influence (Pukkala et al 2010). The incidence of squamous cell carcinoma is decreasing even 
in the countries without a screening program, but in contrast, the incidence of 
adenocarcinoma has been increasing in recent decades, particularly in younger women (Table 
6) (Finnish Cancer Registry 2011, Bray et al 2005). The cause of this phenomenon is 
unknown, but it may be related to changes in living surroundings or hormonal milieu. 
 
Risk factors 
 
It is a present dogma that HPV is a necessity for developing cervical cancers. Most women 
acquire HPV infections, but only in 5% of the infected women HPV persists for several years 
and may lead to cancer. It has been approximated that it takes 10 years from hrHPV infection 
to cause CIN grade 3 lesions (Schiffman et al 2010). Nowadays, over 150 types of HPVs have 
been identified, but only 15 of them are “high risk” or oncogenic viruses (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 68, 73, 82) (Schiffman et al 2011). The hrHPV types 16 and 18 are 
most often encountered in squamous cell carcinoma (70-80%) and adenocarcinoma (30-50 %) 
(Appleby et al 2006, Dahlström et al 2010). The incidence of HPV is highest among young 
women after the initiation of sexual life, and another incidence peak is seen in 
postmenopausal women; the latter may be a result of the reactivation of earlier infection, 
perhaps due to weakened immune defence with advancing age (Burchell et al 2006). 
Hormonal factors may also contribute to the occurrence of HPV.  
 
There is evidence for the role of estrogen as a cofactor in the genesis of cervical cancer. 
Cervical cancers often express ERs and PRs (Table 5) (Hunter et al 1987, Bodner et al 2010). 
It is also known that exogenous estradiol promotes cancer formation in hrHPV infected 
transgenic mice with ERα (see for a review Chung et al 2010). ERα antagonists have also 
been shown to eliminate CIN lesions and cancer in mice. Furthermore, estrogen increases the 
expression of E6 and E7 oncogenes, which are the driving force for cervical cancer (Chung et 
al 2010). In addition, strong observational data on humans show that the current use of oral 
contraceptives is associated with an increased risk for cervical cancers; probably due to 
increased sexual activity (Table 7) (Appleby et al 2007). 
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Obesity and high waist-to-hip ratio have been reported to associate with a 2-fold increased 
risk for adenocarcinoma, and in effect, this risk elevation is of the same magnitude as for 
endometrial or breast cancer (Lacey et al 2003, Chung et al 2010). The role of 
postmenopausal HT as a risk factor for cervical malignancies will be discussed later in this 
presentation (page 34). 
 
Some of the non-viral cofactors for precancerous and cancerous cervical lesions are related to 
sexual behaviour (Table 7) (Appleby et al 2006). Sexually transmitted diseases, especially 
Chlamydia tracomatis, have been linked to an increased risk for CIN grade 2 (Lehtinen et al 
2011). The human immunodeficiency virus suppresses immune defence, and therefore it 
predisposes to cervical precancerous lesions (recurrence, persistence and progression) (Nappi 
et al 2005). Smoking is regarded as an independent risk factor for squamous cell carcinoma 
but not for adenocarcinoma (Appleby et al 2006). Vaccination against hrHPV infection 
reduces the occurrence of cervical precancerous lesions (Tjalma et al 2004, Schiffman and 
Wentzen 2010, Lehtinen et al 2012), but it will not reduce the burden of cervical malignancies 
in the next decade in Finland (Finnish Cancer Registry 2009). In many countries, hrHPV 
vaccination is a part of a national vaccination program, but in Finland the issue is under 
consideration by the Ministry of Social Affairs and Health. 
 
 
Table 7. Risk factors for cervical cancer. 
Squamous cell carcinoma Adenocarcinoma 
High risk HPV infection High risk HPV infection 
Many sexual partners Many sexual partners 
Young age at first intercourse Young age at first intercourse 
Young age at first delivery Young age at first delivery 
Oral contraceptive use Oral contraceptive use 
High parity  Obesity 
Smoking Human immunodeficiency virus infection 
Human immunodeficiency virus infection  
Chlamydia   
Low social class  
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Postmenopausal hormone therapies 
 
During perimenopausal transition, the levels of circulating estrogens decline. Menopause is 
defined as the last menstrual bleeding, and this typically happens at the age of 51 years in 
Finland (Luoto et al 1994). It is followed by estrogen deficiency, which causes 
postmenopausal symptoms. Immediate symptoms such as hot flushes, night sweats, sleep 
disturbances, mood changes, tachycardia and palpitation may appear and decrease the quality 
of life of menopausal women. The majority (80%) of women face some of these symptoms, 
but their severity varies; 20% find the symptoms intolerable (Table 8) (see for a review Blake 
2008). Vasomotor symptoms may disappear with time, but one third of women have them for 
5 years or more, e.g., about 10% of Swedish women report vasomotor symptoms still at the 
age of 70 years (Blake 2008). Vaginal dryness, dyspareunia and recurrent urinary tract 
infections are also common (50%) (Hichey et al 2005). These symptoms force women to seek 
alleviation from postmenopausal therapies.  
 
Estrogen-only therapy 
 
Estrogen-only therapy (ET) is defined as the systemic use of solely estrogen by 
postmenopausal women. Systemic estrogen can be administrated orally as tablets or 
transdermally as a gel or patches. Conjugated equine estrogens, which are isolated from 
pregnant mares’ urine, are commonly used in the US, while in Europe, synthetic 17beta-
estradiol is popular and practically the only estrogen in Finland. Estrogen-only therapy was 
commonly used until the mid-1980s, when it was shown to increase the risk for endometrial 
hyperplasia and cancer (Judd et al 1996). Therefore ET is now restricted only for 
hysterectomized women in Finland (Finnish Consensus Statement 2004, International 
Menopause Society 2007, North American Menopause Society 2010).  
 
Estrogen can also be administrated directly into vagina as a vaginal cream, tablet or vaginal 
ring. Such a treatment is effective for urogenital atrophy (Robinson and Cardozo 2011). A 
circulation level of estrogen may slightly elevate for 2-3 months after the initiation of vaginal 
estrogen administration, but it is generally assumed that such a therapy does not have any 
systemic effects, and, e.g., the risk of breast cancer is not elevated (Lyytinen et al 2006). 
Estrogen used vaginally has not shown to increase the risk for endometrial cancer 
(Weiderpass et al 1999, Epstein et al 2009). 
 
 
Table 8. Principal menopausal symptoms and their frequency. 
Vasomotor symptoms (80%) Urogenital atrophy (50%)  Mood changes  
Hot flushes (60%) Vaginal dryness (27-55%) Sleep disturbances (30%) 
Night sweats Dyspareunia (32-41%) Depressed mood (19-29%) 
Tachycardia  Overactive bladder symptoms Irritability 
Palpitation (20%) Urinary tract infections Anxiety 
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Estrogen-progestagen therapy 
 
Progestagens are added to estrogen to protect the endometrium against hyperplasia and cancer 
(Stanczyk 2003, Davis et al 2005, Archer et al 2007). Estrogen-progestagen therapy (EPT) is 
sequential when progestagen is added to continuous estrogen in 10-14 day phases monthly or 
every 3 month (long-cycle). When progestagen is taken daily concomitantly with estrogen, it 
is defined as continuous combined EPT. Continuous combined regimens, which cause 
endometrial atrophy and the consequent amenorrhea, have become increasingly popular from 
the late 1980s onwards (Campagnoli et al 2005). Constant estrogen and intermittent 
progestagen use (3 days on-off) has also been described (Rozenberg 2001). Types and doses 
of progestagens and estradiol in fixed commercial products in Finland are shown in the 
following table (Table 9) (Lyytinen et al 2010). 
 
 
Table 9. Content of the commercial sequential estradiol-progestagen therapy (EPT) 
products in Finland
1
.
 
 
Type of progestagen Dose of progestagen (mg) Dose of estradiol (mg) 
Oral   
Norethisterone acetate 1 1 or 2 
Medroxyprogesterone acetate 
Medroxyprogesterone acetate2 
10 
20 
2 
2 
Levonorgestrel 0.25 2 
Dydrogesterone 10 
20 
1 or 2 
2 
Trimegestone 0.5 2 
Transdermal   
Norethisterone acetate 0.17 or 0.25 0.05 
Levonorgestrel 0.01 
0.02 
0.05 
0.065 
Continuous EPT, type of 
progestagen 
  
Oral   
Norethisterone acetate 0.5  
1 or 0.7 
1 
2 
Medroxyprogesterone acetate 2.5 or 5 
5 
1 
2 
Dydrogesterone 5 1 
Drospirenone 2 1 
Transdermal   
Norethisterone acetate 0.17 or 0.25 0.05 
1Reproduced with permission (Lyytinen et al 2010, Wiley-Blackwell). 
2Long-cycle, progestagen for 14 days every 3rd month. 
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Progestagens can be classified as natural progesterone and as synthetic progestagens. 
Synthetic types can be 17alfa-hydroxyprogesterone derivatives (e.g., medroxyprogesterone 
acetate (MPA), dydrogesterone, trimegestone) whose structure resembles natural progesterone 
or 19-norprogesterone derivatives (e.g., norethisterone acetate (NETA), levonorgestrel 
(LNG)) which structurally resemble testosterone. Pharmacokinetics, metabolism and potency 
of different progestagens vary markedly (Stanczyk 2003). 
 
Synthetic progestagens are most commonly used as parts of EPT, but micronized 
progesterone has also been used. Various types of progestagens are used in different 
countries; MPA is almost the only progestagen used in the US, whereas NETA and LNG are 
popular in Scandinavia and the UK, and micronized progesterone and dydrogesterone in 
Central and Southern Europe (Campagnoli et al 2005). Progestagens as a part of EPT forms 
the cancerous effect, e.g., in the breast (see Lyytinen 2009), but progestagens show some 
differences in this regard (Fournier et al 2008, Lyytinen et al 2009). 
 
Tibolone 
 
Tibolone is a synthetic steroid which is metabolized in the liver and intestine to estrogenic, 
progestagenic and androgenic metabolites. In the endometrium, tibolone is converted into the 
Δ4-isomer, which prevents endometrial proliferation, thus causing no withdrawal bleeding 
(Biglia et al 2010). Tibolone as a daily dose of 2.5 mg, reduces postmenopausal vasomotor 
symptoms, protects from osteoporosis and may improve sexual function (Santen et al 2010). 
It has been on the market since 1988 in Europe, and worldwide it has been used in over 1.5 
million women-years (Biglia et al 2010). It has been available in Finland since 1995, and 
approximately 15,000 women used tibolone in 2008 according to The Social Insurance 
Institute of Finland.  
 
Route of administration  
 
Estrogen as a part of HT can be administrated orally or transdermally. Transdermal 
administration of estrogen avoids hepatic first pass metabolism, and it results in more positive 
vascular effects including a lack of thromboembolic risk. (Straczek et al 2005, L’Hermite et al 
2008, Tuomikoski 2010, North American Menopause Society 2010). 
 
Other hormonal modalities 
 
Selective estrogen receptor modulators (SERMs), testosterone and phytoestrogens have also 
been studied for the treatment of menopausal symptoms.  
 
By definition, SERMs are synthetic compounds which bind to estrogen receptors and act as 
an estrogen agonist or antagonist, depending on the tissue (Shelly et al 2008). It is unclear 
which factors determine the final effect of a given SERM (Davis et al 2005), and each SERM 
may have a unique clinical response (Shelly et al 2008). Tamoxifen and toremifen are the 
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most common SERMs and are used as an adjuvant treatment for premenopausal breast cancer 
patients. Raloxifene is primarily used for the prevention and treatment of osteopenia / -porosis 
in postmenopausal women. One of the drawbacks of the use of SERMs is the appearance of 
hot flushes, and therefore, low dose-estrogen has been combined with SERMs in some 
clinical studies (Kharode et al 2008, Lobo et al 2009).  
 
Testosterone orally or transdermally (with or without estrogen) has been studied for treating 
hyposexual desire disorder in naturally or surgically menopausal women (Davis et al 2006). 
The transdermal testosterone patch may improve libido, but it is unlikely that it is indicated in 
women using concurrent ET/EPT (Santen et al 2010).  
 
Phytoestrogens are natural polyphenols which may bind to estrogen receptors. Phytoestrogens 
derive from plants, and this group includes flavones, flavanones, isoflavones, coumarins, 
chalcones, lignants and stilbenes (Leclercq et al 2011). Even though phytoestrogens are often 
proposed to alleviate menopausal symptoms, truly placebo-controlled trials have failed to 
show any specific effect for phytoestrogens in the treatment of menopausal symptoms 
(Nikander 2004, Leclercq et al 2011).  
 
Effects of postmenopausal hormone therapy 
 
Abundant data have accumulated on the effects of HT (Table 10 and 11). Level of evidence is 
given in the table and it is graded according to the Endocrine Society Scientific Statement  
 
Table 10. Beneficial effects of hormone therapy expressed with level of evidence. 
Modified according to the Endocrine Society Scientific Statement (Santen et al 2010). 
High  Moderate Low/very low 
Hot flushes Degenerative arthritis  Age-related skin changes 
reduced 
Bone and fractures 
 
Arthroplasty rate reduced  
Urogenital system symptoms 
(atrophy, over active bladder, 
urine tract infections) 
 
Short term verbal memory 
benefit after surgical 
menopause 
Long term risk of dementia 
decreased 
Colon cancer risk decreased Quality of life through 
decreased symptoms 
 
Macular degeneration 
reduced 
 Sexual function 
 
 
 Coronary heart disease 
(initiation near menopause) 
 
 
 Diabetes mellitus type 2  
 Body Weight/BMI/Fat 
distribution  
 
 
 Overall mortality  
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(Santen et al 2010). A systemic ET and EPT is the most effective treatment for hot flushes 
and urogenital atrophy. These treatments also protect against osteoporosis and bone fractures, 
but this benefit is rapidly lost after cessation of HT. If hormone therapy is initiated soon after 
the onset of menopause, the risk of myocardial infarction and other vascular events may be 
reduced (Rossouw et al 2007, see for a review Tuomikoski et al 2011), but if the initiation is 
postponed by 10-15 years after the onset of menopause, the risk of vascular events is 
increased (Hulley et al 1998, Rossouw et al 2002). Hormone therapy has also been shown to 
reduce the risk for diabetes also in Finland (Pentti et al 2009). Women using HT at the age of 
less than 60 years have shown a 39% reduced overall mortality rate in a meta–analysis of 30 
randomized trials (Salpeter et al 2004). The use of HT for 5-30 years, initiated at the age of 
50, has also shown to increase quality adjusted life-years, and it has shown to be highly cost-
effective (Salpeter et al 2009). Nevertheless, the recent evaluation of HT research reinforces 
current guidelines on the use of systemic HT; it is appropriate for immediate vasomotor 
symptoms but not for chronic disease prevention (Taylor and Manson 2011). However, there 
is no time limit for HT use; the further need for HT can be evaluated by reassessing the 
reoccurrence of possible symptoms during a break in the medication. The most common 
adverse effects of HT are disturbances in uterine bleeding, breast tenderness, increased breast 
density in mammography and increased risk for thromboembolism and gallbladder disease 
(Table 11).  
 
Carcinogenetic effects of HT have been a major concern for decades among HT users and 
doctors prescribing them (Creasman 2002). Estrogen is known to influence the risk for breast 
cancer, and the long-term use of either ET or EPT is accompanied by modest rises in the risk 
but EPT carries a higher risk than ET only (Collins et al 2005). Basically, similar data were 
also recently reported from Finland ( Lyytinen 2009). In contrast, the use of EPT is be 
associated with a decreased risk for colon cancer (Chlebowski et al 2004). The use of estrogen  
 
 
Table 11. Adverse effects of hormone therapy expressed with level of evidence. Modified 
according to the Endocrine Society Scientific Statement (Santen et al 2010). 
High  Moderate 
Mammographic density 
 
Coronary heart disease risk (late initiation) 
Gallbladder disease 
 
Stroke risk 
 
Venous thromboembolism 
 
Vascular dementia (if initiation age ≥ 65 y) 
Breast cancer recurrence risk Breast cancer risk 
 
 Colon cancer at more advanced stage at the 
time of the diagnosis 
 
 Ovarian cancer risk  
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has been associated with an increased risk for ovarian cancer, and this risk has been reduced 
by adding a progestagen (Pearce et al 2009). The effects of hormone therapy on the risk for 
extra uterine malignancies are summarized in the table 11 (Santen et al 2010). Uterine cancers 
such as endometrial and cervical cancers and uterine sarcomas in relation to hormone therapy 
will be discussed in following chapters. 
 
Postmenopausal hormone therapy and risk for uterine malignancies 
 
Endometrial cancer 
 
Most of the studies assessing the EPT and endometrial cancer risk are retrospective cohort or 
case-control studies. The large British study is a prospective cohort study (Beral et al 2005) 
and the Women’s Health Initiative (WHI) is the only large randomized controlled trial (RCT), 
but assessing only continuous combined EPT regimen containing 0.625 mg of CEE and 2.5 
mg of MPA daily (Andersson et al 2003). 
 
Endometrial cancer risk is known to increase with unopposed estrogen use 6-11-fold in long-
term use (Weiderpass et al 1999, Doherty et al 2007). With opposed estrogen use, the risk is 
dependent on progestagen continuity (Lethaby et al 2004, International Agency for Research 
on Cancer 2007). Different mode of regimens and duration of progestagen phase are main 
variants in the trials assessing EPT and the risk for endometrial cancer (Table 12). Many 
studies exist which do not assess different modes of EPT, and they are excluded from the 
table. There are also differences in the estrogens used; conjugated equine estrogen is used in 
the US and estradiol in most European studies. Progestagens also vary; MPA in the US and 
various progestagens in European trials. Transdermal routes of administration of estrogen or 
EPT have been rarely assessed. Intrauterine administration with levonorgestrel releasing 
intrauterine system (LNG-IUS) is more often used as a contraceptive (Lähteenmaki et al 
2000). As a part of postmenopausal hormonal therapy, LNG-IUS has been evaluated only in 
short-term treatments. Data on the effects of truly long-term use of transdermal HT and 
tibolone are still insufficient (Davis et al 2005). Data of endometrial effects of tibolone are 
also sparse and mainly collected as secondary endpoints in osteoporosis prevention trials. 
Large variation in the used HTs makes the comparison of mode of regimen and route of 
administration difficult, and national studies have been suggested (Cogliano et al 2005).  
 
Sequential estrogen-progestagen therapy 
 
The first sequential EPT studies on the safety of the endometrium focused on the duration of 
progestagens phase (Table 12). The present consensus is that the progestagen course ≥ 10 
days / month is adequate for endometrial safety (International Agency for Research on Cancer 
2007). Then the total duration of EPT use has risen into the focus. The British study found no 
risk excess during an average of 5.1 years follow-up (Beral et al 2005), but the nationwide 
Swedish (Weiderpass et al 1999) and American case-control studies (Doherty et al 2007) have 
shown increased risks for sequential use of progestagen after 5-6 years of use (Table 12).  
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Table 12. Studies assessing the effect of postmenopausal monthly sequential estrogen-
progestagen therapy on the risk for endometrial cancer (EC). 
Study  Size of 
study 
EC cases / 
duration of 
use / days 
of 
progestagen 
Design Days of 
proges-
tagen / 
month  
Duration 
of use 
(years) 
Relative Risk  
(95% CI) 
Beresford 
et al 1997 
 
832/1114 30 
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retrospective 
case-control 
< 10 
10-21 
≥ 5 
≥ 5 
3.7 (1.7-8.2) 
2.5 (1.1-5.5) 
Pike  
et al 1997 
 
833/791 74 
79 
 
retrospective 
case-control 
< 10 
≥ 10 
5 
5 
1.87 (1.32-2.65) 
1.07 (0.82-1.41) 
Weiderpass 
et al1 999 
 
709/3368 38 
40 
 
nationwide, 
retrospective  
case-control 
10-16 < 5  
≥ 5  
1.5 (1.0-2.2) 
2.9 (1.8-4.6) 
Beral  
et al 2005 
 
145 500 242 prospective 
cohort 
10-14 average 
5.1  
1.05 (0.91-1.22) 
Lacey  
et al 2005 
 
 
 
30 379 5 
7 
5 
15 
 
retrospective 
cohort 
< 15 < 2 
2-3 
4-5 
≥ 6 
1.3 (0.5-3.2) 
2.4.(1.1-5.3) 
2.5 (0.99-6.2) 
5.7 (3.2-10.2) 
Lacey  
et al 2007 
 
73 211 3 
8 
retrospective 
cohort 
10-14 2-4 
> 5 
0.85 (0.27-2.70) 
0.79 (0.38-1.66) 
Doherty  
et al 2007 
1038/1453 14 
8 
25 
 
17 
15 
30 
 
retrospective 
case-control 
<10 
 
 
 
10-24 
< 3 
3-6 
≥ 6 
 
< 3 
3-6 
≥ 6 
2.4 (1.1-5.4) 
3.2 (1.1-8.7) 
5.9 (2.9-12) 
 
0.94 (0.51-1.7) 
1.2 (0.60-2.2) 
2.0 (1.2-3.5) 
Razavi  
et al 2010 
311/570 13 
10 
12 
 
4 
7 
4 
retrospective 
case-control, 
cohort 
<10 
 
 
 
10-24 
< 5 
5-9 
10+ 
 
< 5 
5-9 
10+ 
1.41 (0.65-3.06) 
1.87 (0.74-4.73) 
4.35 (1.68-11.22) 
 
0.48 (0.14-1.68) 
1.30 (0.46-3.68) 
0.91 (0.29-2.91) 
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In the Nordic countries sequential long-cycle EPT, which includes the addition of 14 days of 
progestagen each 3 months to continuous estradiol, has been popular. This type of EPT 
carried an increased risk for endometrial hyperplasia (5.6%), compared to sequential monthly 
EPT (1%) in 4 years follow-up (Bjarnason et al 1999). The sequential long-cycle EPT, given 
for four years, was accompanied with a 2-fold elevation in the risk of endometrial cancer in 
Finland (Pukkala et al 2000). This implies that infrequent progestagen phases at 3 months 
intervals may not fully oppose estrogen- induced endometrial proliferation. If such a regimen 
is used, endometrial monitoring with ultrasound examination and endometrial biopsies is 
necessary.  
 
Continuous combined estrogen-progestagen therapy 
 
Several RCTs have studied the endometrial safety of continuous combined EPT regimens up 
to 10 years (van de Weijer et al 2006, Heikkinen et al 2006). This type of EPT has been safe 
for the endometrium, and this protection appears to be highest in obese women (Beral et al 
2005, Crosbie et al 2010). Oral continuous combined estradiol (2 mg) and norethisterone 
acetate (1mg) for 9 months can even be curative for endometrial complex hyperplasia and 
maintain the endometrium atrophic up to 5 years (Wells et al 2002). The addition of 
progestagen continuously to estrogen negates the cancer promoting effect of estrogen in the 
endometrium in most studies (Weiderpass et al 1999, Beral et al 2005, Doherty et al 2007) 
(Table 13). In a placebo-controlled WHI trial, the endometrial cancer risk was 0.81(0.48-1.36) 
with continuous CEE/MPA given for 5.6 years. This risk decrease was not significant, maybe 
because the study population included women who were first randomized to an ET-only 
group, women started EPT use at an advanced age (mean age of 63 years), and a majority of 
them were overweight. These could explain the lack of significance in the study. Other 
notable factors included careful endometrial monitoring and the exclusion of women with 
endometrial hyperplasia before inclusion (simple hyperplasia during the follow-up was 
treated). A rather short follow-up may perhaps also explain the lacking significance in the 
decrease of endometrial cancer risk (Andersson et al 2003) (Table 13). 
 
Intrauterine system releasing 20 μg levonorgestrel of per 24 hr is used in combination with a 
systemic estrogen as one form of continuous combined EPT. It has been reimbursed as part of 
menopausal hormone therapy in Finland since 1997. Estradiol plus levonorgestrel intrauterine 
system (LNG-IUS) has been shown to cause a non-proliferative endometrium after 1 year of 
use (Suvanto-Luukkonen and Kauppila 1999, Varila et al 2001, Hampton et al 2005). This 
comes as no surprise, as the sole use of LNG-IUS can cure endometrial hyperplasia (see for a 
review Varma et al 2006) and perhaps prevent endometrial polyps in breast cancer patients 
using tamoxifen (Chan et al 2007). The liberal use of LNG-IUS in fertile and postmenopausal 
obese women is also suggested as prevention for endometrial cancer (Leslie 2012). 
Levonorgestrel intrauterine system has been inserted as a treatment for early stage 
endometrial cancer in small case series with and without oral progestagen. Some have 
reported cancer regression in 75% of cases at 12 months, but new cancers after LNG-IUS 
insertion have also appeared.  
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Table 13. Studies assessing the effect of postmenopausal continuous combined estrogen-
progestagen therapy (EPT) on the risk for endometrial cancer (EC). 
Study 
 
Size of 
study  
EC cases 
/duration of 
use/in 
exposed vs 
placebo 
group 
Design  Days of 
proges-
tagen/ 
month 
Duration 
of use 
(years) 
Relative Risk 
 (95% CI) 
Pike  
et al1 1997 
 
833/791 94 retrospective  
case-control 
28  ≥ 5 1.07 (0.80-1.43) 
Weiderpass  
et al 1999 
709/3368 32 
2 
nationwide  
retrospective  
case-control 
 
≥19  
28 
< 5 
≥ 5  
0.8 (0.5-1.3) 
0.2 (0.1-0.8) 
 
Hill  
et al 2000 
 
969/1325 9 retrospective 
 case-control 
10-24 < 6 0.4 (0.2-1.1) 
Hulley  
et al 2002 
 
1380/1383 2/8 randomized 
controlled 
trial 
 
28 6.8 0.25 (0.05-1.18) 
Andersson  
et al 2003 
8506/8102 27/31 randomized 
controlled 
trial 
 
28 average 
5.6 
0.81 (0.48-1.36) 
Beral  
et al 2005 
 
69 600 73 prospective 
cohort 
28 average 
5.0  
0.71 (0.56-0.90) 
Lacey  
et al 2005 
30 379 
 
3 
6 
3 
3 
retrospective 
cohort 
>15 < 2 
2-3 
4-5 
≥ 6 
1.1 (0.3-3.4) 
3.9 (1.7-9.2) 
2.9 (0.9-9.4) 
4.2 (1.3-13.6) 
 
Lacey  
et al 2007 
73 211 
 
1 
14 
20 
 
retrospective  
cohort 
≥ 20 ≤1 
2-4 
> 5 
0.12 (0.02-1.01) 
0.92 (0.61-1.85) 
0.67 (0.53-1.36) 
Doherty  
et al 2007 
1038/1453 
 
14 
11 
27 
retrospective  
case-control 
≥ 25 < 3 
3-6 
≥ 6 
0.45 (0.23-0.88) 
0.51 (0.24-1.1) 
0.77 (0.45-1.3) 
 
Razavi  
et al 2010 
311/570 
 
44 
27 
47 
retrospective 
case-control, 
cohort 
≥ 25 < 5 
5-9 
10+ 
0.86 (0.55-1.35) 
0.81 (0.48-1.37) 
2.05 (1.27-3.30) 
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Therefore, further controlled trials with LNG-IUS and with longer follow-up are required on 
women with endometrial pathology (Varma et al 2006).  
 
Data about transdermal administration of EPT on the risk of endometrial hyperplasia are 
sparse (Ylikorkala and Rozenberg 2000). It is questionable whether transdermal 
administration of natural progesterone yields an adequate endometrial protection (Stanczyk 
2005), and in the US such use of progestagen is not recommended (Utian et al 2010). 
 
Tibolone 
 
The endometrial effect of tibolone users is conflicting (Table 14). In the British study, the risk 
for endometrial cancer was elevated by 79% (Beral et al 2005). Three randomized placebo-
controlled bone studies have evaluated the endometrial safety as the secondary endpoint, and 
tibolone at 1.25 and 2.5 mg daily doses up to three years did not associate with any changes in 
the endometrial cancer risk (Langer et al 2006, Archer et al 2007, Ettinger et al 2008). 
 
 
Table 14. Studies assessing the effect of postmenopausal tibolone use on the risk for 
endometrial cancer (EC). 
Study 
Year 
Size of 
study 
EC 
cases 
Age Duration 
of use 
(years) 
Design Relative Risk 
(95% CI) 
de Vries et al 
2005 
4995 43 40-74 7.1 cohort, nested case-
control 
 
1.54 (1.03-2.32) 
Beral et al 
2005 
 
28 000 86 58 
(mean) 
average 
5.2 
prospective cohort 1.79 (1.43-2.25) 
Langer et al  
2006 
866 2 45-79 3 tibolone (2.5 mg/d) 
compared to 
continuous E/MPA 
(0.625+2.5mg/d) 
 
Similar  
endometrial  
safety 
Archer et al 
2007 
3224 0 45-65 2 tibolone (1.25 or 2.5 
mg/d) compared to 
continuous E/MPA 
(0.625+2.5mg/d) 
 
Similar 
endometrial 
safety 
Ettinger et al  
2008 
3519 4 60-85 3 tibolone (1.25 mg/d) 
compared to placebo 
A marginal  
increase in risk 
for EC 
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Uterine sarcomas  
 
Except for one case report (Altaras et al 1990), no true research data exist on postmenpausal 
hormone therapy as a risk factor for uterine sarcomas. Endometrial stromal sarcoma patients 
treated postoperatively with ET or tamoxifen have showed an increased recurrence rate. In 
small patient series, 4/5 and 5/10 patients receiving ET and 3/10 tamoxifen users’ uterine 
sarcoma recurred (Chu et al 2003, Pink et al 2005). The sparse previous data on the possible 
association between HT and uterine sarcomas call for large, preferably nationwide studies. 
 
Cervical cancer 
 
The association of postmenopausal HT and cervical cancer is rarely assessed due to the fact 
that HT is predominantly used in the countries with a low incidence of cervical cancer. There 
are only few studies in this field, and their statistical power is insufficient (International 
Agency for Research on Cancer 2007). The use of EPT shows no increase in the prevalence 
of HPV infection (Smith et al 2002). In two-year follow-up of RCT, the use of continuous 
combined EPT did not affect the incidence of cytological abnormality (relative hazard 1.36, 
CI 0.93-1.99) in 2,561 EPT users (Sawaya et al 2000). In the WHI trial on 15,733 
postmenopausal women (aged 50-79), the use of continuous combined CEE/MPA was 
associated with a higher incidence of any new cytological abnormality in cervical smears 
(hazard ratio 1.4, 95% CI 1.2-1.6). However, occurrence of high-grade squamous cell 
intraepithelial lesions (n = 54) or invasive cancers (n = 10) was not increased in an average of 
5.6 years follow-up (Yasmeen et al 2006). 
 
Estrogen-only therapy has been associated with a duration-dependent trend for a decrease in 
the risk for cervical cancer (OR 0.5; 95% CI 0.3-0.8) ((Parazzini et al 1997). Unfortunately, 
the status of HPV infection or cervical cancer type was not known in this study. When the use 
of HT and risk for both cervical cancer types were separately analysed, the results showed a 
trend for an increased risk for adenocarcinoma (n = 13) (odds ratio (OR) 2.1, 95% CI 0.95-
4.6) and a trend for a decreased risk for squamous cell carcinoma (n = 7) (OR 0.85, 95% CI 
0.34-2.1); the number of cases was small (Lacey et al 2000). 
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AIMS OF THE STUDY 
 
The purpose of my thesis was to evaluate the impact of postmenopausal EPT regimens and 
tibolone on the risk for uterine cancers in Finnish postmenopausal women by a retrospective, 
registry-based nationwide cohort and case-control studies. Analyses were conducted to see 
whether the various progestagens, mode of EPT regimens or various routes of EPT 
administration were determinants for the possible relations between EPT or tibolone and 
cancer risks. The cancers evaluated were 
 
1. endometrial cancer (Studies I and II) 
 
2. uterine sarcomas (Study III)  
 
3. cervical precancerous and cancerous lesions (Study IV) 
36 
 
SUBJECTS AND METHODS  
 
Study populations  
 
Cohort studies 
 
The study cohort for Study I included all Finnish women over 50 who have received 
reimbursement for the systemic EPT used for at least 6 months in 1994-2006 (n = 224,015). 
For Studies III and IV, the cohort was updated to the end of 2008 (n = 243,857). The women 
in the cohort were collected from the Medical Reimbursement Register of The Social 
Insurance Institution of Finland. The EPT cohort dated up to the end of 2008 produced over 2 
million person-years. The proportion of the EPT cohort to the total of age-matched Finnish 
postmenopausal female population varied between 1.9% and 25% (Table 15). 
 
At the year of the registry’s opening in 1994, part of the women who bought EPT products 
had evidently also used EPT before 1994. Therefore, the cohort was split into those with more 
than 5 years of EPT use after 1994, with possible pre-registry EPT use, and to “fresh users” 
who initiated the use of EPT in 1995 or later (Figure 4). The latter women were employed to 
compare various EPT regimens in shorter exposure times (< 5 years). The follow-up of 
women, who underwent hysterectomy in the cohort studies, was discontinued at the 
hysterectomy date (Table 16). 
 
 
 
 
Table 15. Proportions of person-years in the estradiol-progestagen therapy (EPT) 
cohort 1994-2008 from the total population, by age. 
Age EPT Cohort Total % 
50-54 427 391 2 866 100 14.9 
55-59 642 849 2 568 700 25.0 
60-64 464 760 2 150 500 21.6 
65-69 274 258 1 929 500 14.2 
70-74 130 017 1 789 800 7.3 
75+ 69 706 3 584 100 1.9 
Total 2 008 981 14 888 700 13.5 
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Case-control study 
 
All Finnish women between the age of 50-80 years with endometrial cancer were identified 
from the Finnish Cancer Registry (n = 7,261) in 1995-2007. For each case, three control 
women with an intact uterus born at the same time ( +/- one month) as the case, alive and 
without endometrial cancer at the time of the diagnosis of the case were randomly selected 
from the Finnish National Population Register (n = 19,490). The population register also 
provided parity data from the dates of children born since the 1st of October 1953 for cases 
and controls. The age of the cases and the controls at the deliveries were calculated from the 
parity data. The hospital district of the patients and controls was also available. Results were 
adjusted for parity, age at first delivery and hospital district, but not for body mass index, 
diabetes mellitus, smoking or socioeconomic status. Women who had undergone 
hysterectomy (n = 2,293) were excluded from the controls. The use of EPT for cases and 
controls was studied with through a linkage to the Medical Reimbursement Registry. The 
study population and HT exposure data are illustrated in the lexis diagram. For those with HT 
use before 1994, initiation of HT was estimated at the age of 52 (Figure 5).  
 
 
 
Figure 4. Selection of the study cohort of women using estradiol-progestagen therapy in 
Finland 1994-2008. 
 
 
 
Registry opened 1994; 
estradiol-progestagen 
therapy users1994-2008 
N = 275,522 
Women included 
n=243,857 
Users at registry opening / 
Registered use started 1994 
(Pre-registry use possible)  
 n=104,933 
Excluded; 
estradiol-progestagen therapy 
used less than 6 months 
n= 31,665 
Fresh users / Registered 
use started 1995-2008 
(Completely known use) 
n=138,924 
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Figure 5. Lexis diagram of study population and hormone therapy (HT) exposure time. 
  
 
 
Registries 
 
All studies were based on established registries (Table 16). The data about uterine cancers 
were obtained from the Finnish Cancer Registry with personal identity codes. Uterine cancers 
diagnosed from 1994 to 2006 have been originally coded with ICD- 07 and MOTNAC codes 
and converted to the codes of International Classification of Disease for Oncology, Third 
Edition in 2007 (Finnish Cancer Registry 2009).  
 
The Hospital Inpatient Register of the National Institute of Health and Welfare has piled up 
surgical procedures since 1986. The coverage of the registry is almost complete (Keskimäki et 
al 1994). Hysterectomies were handled in each study as indicated in the table (Table 16). 
 
Statistical methods 
 
In the cohort studies, the number of observed uterine malignancies among EPT users was 
divided by the expected numbers of the general population (standardized incidence ratios, 
SIRs). The expected numbers of women with uterine cancers in 5-year age groups 
calculations were based on the whole country cancer statistics; the number of woman-years in 
each 5-year age group was multiplied with corresponding uterine malignancies incidences 
among all Finnish women during the same period of observation. Ninety-five per cent 
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Table 16. Registries used in present studies. 
Register Data available Number of 
study  
Study period 
Medical Reimbursement 
Registry (Social Insurance 
Institution of Finland) 
All systemic hormone 
therapy reimbursed since 
1994 
Study I 
Study II 
Study III 
Study IV 
1994-2006 
1994-2007 
1994-2008 
1994-2008 
Finnish Cancer Registry Incident cancers and 
cancer deaths since 1953 
Study I 
Study II 
Study III 
Study IV 
1994-2006 
1995-2007 
1994-2008 
1994-2008 
Hospital Inpatient Register 
(National Institute of Health 
and Welfare) 
Hysterectomies 
performed since 1986 
Study I 
Study II 
Study III 
Study IV 
1986-2003 
1986-2003 
1994-2008 
1994-2008 
Finnish Population Register 
Centre 
Personal identity codes 
for all alive since 1967 
Study II 1995-2007 
 
 
confidence intervals (95% CIs) were defined for each SIR. The number of observed cases was 
assumed to represent a Poisson distribution (Rothman 1998). Heterogeneity was tested in 
Study IV with Poisson regression analyses. 
 
The follow-up for EPT users in all cohort studies started in 1994 and ended in Study I at 
emigration, death, hysterectomy or at the end of 2006. In Studies III and IV, the closing date 
was the end of 2008. In Study I, the follow-up ended one month after hysterectomy, but in 
later studies the follow-up was discontinued four months after the hysterectomy because in 
the case of uterine sarcomas, the final diagnoses may have taken a longer time. 
 
A multivariate conditional logistic regression model was used to estimate, by means of the 
odds ratio (OR), the relative risk for endometrial cancer associated with each category of HT 
use in the case-control study (Study II). The ages at first and last delivery, and parity, were 
considered as possible confounders, and testing for possible interactions between the variables 
was based on the likelihood ratio statistics. Estimates of the model parameters and 95% 
confidence intervals (CIs) were computed by the maximum likelihood technique.  
 
Ethics and permissions 
 
This study, which has been approved by the Helsinki University Hospital Ethics Board 
(Number 298/E9/06), was conducted with permission from The National Institute for Health 
and Welfare and the Social Insurance Institution of Finland. 
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RESULTS  
 
Only the main results are presented here, and further details are shown in the original 
publications. 
 
Endometrial cancer 
 
Cohort study (I) 
 
A sequential EPT was more common (54%) than a continuous one (23%), and only 2% used 
long-cycle sequential EPT (Figure 6). Oral use of EPT was favored over the transdermal 
mode (86% vs. 7%).  
 
Of different progestagens as part of EPT, NETA was the most popular progestin (44%), 
followed by MPA (27%) and dydrogesterone (12%) (Figure 7). The other progestagens (10%) 
as parts of EPT were levonorgestrel, megestroleacetate, progesterone, lynesterol, trimegestone 
and drospirenone.  
 
 
Figure 6. Mode of estradiol-progestagen therapy regimens used in Finland 1995-2006  
(N = 121 036). Figure 6 . Mode of EPT regimens used in Finland 1995-2006 (N=121,036)
Sequential
52 %
Other/mixed cont.
18 %
Unclassified
5 %
Long-cycle
 (3-monthly)
2 %
Continuous
23 %
 
 
 
41 
 
Figure 7. Distribution of progestagens in estradiol-progestagen therapy regimens used in 
Finland 1995-2006 (N = 121 036). 
 
 
 
In cohort study (I), a total of 1,364 patients with type I and 38 patients with type II 
endometrial cancers were encountered. The use of continuous combined EPT was associated 
with a reduced risk for endometrial cancer type I after 3 years of use (SIR 0.24; 0.06-0.60), 
and this protection persisted up to 10 years (0.36; 0.19-0.62) (Figure 8). 
 
 
Figure 8. Standardized incidence ratios (SIR) of endometrial cancer among continuous 
combined estradiol-progestagen therapy users (n = 34 403) as expressed against the 
exposure time. 
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Sequential (monthly) EPT use was associated with an increased risk for endometrial cancer 
after 5 years of use (1.69; 1.43-1.96), and this risk increased further with an extended 
exposure time up to 10 years (2.56; 1.28-4.58) (Figure 9). After 5 years of use, the risk was 
highest for the use of long-cycle (3 monthly) EPT (3.76; 2.90-4.79) and after 10 years the risk 
increased up to 6-fold (6.64; 1.81-16.99). Mixed use of EPT, i.e., switching mode of EPT, 
was also associated with an increased risk for endometrial cancer after 5 years of use (2.34; 
2.12-2.57) (Figure 9). 
 
Among monthly sequential EPT users, endometrial cancer tended to be diagnosed more often 
in a localized phase (1.79; 1.51-2.10) than in the reference population. 
 
Progestagens (MPA, NETA and Dydrogesterone) as parts of oral sequential (monthly) EPT 
products showed no significant differences in endometrial effect (Table 17). 
 
The route of administration and risk for endometrial cancer was compared with sequential 
EPT with norethisterone acetate-progestagen. There were no significant differences between 
the oral (1.75; 1.32-2.26) and transdermal (2.43; 1.42-3.89) regimen after 5 years of use 
(Table 17). 
 
 
Figure 9. Standardized incidence ratios (SIR) of endometrial cancers according to the 
mode of sequential and mixed estradiol-progestagen therapy use (n = 198 296). 
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Table 17. Number of endometrial cancer cases (OBS) and expected cases (EXP) in 
women aged >50 years using sequential estradiol-progestagen therapy 1994-2006 (N) 
and Standardised Incidence Ratios (SIR) with 95% confidence interval (CI), by 
duration of use and route of progestagen administration. 
Adminis-
tration  
6 months to less than 5 years
1 
 
5 years or more
2
 
N OBS EXP SIR 95% CI N OBS EXP SIR 95% CI 
Oral 
NETA3 17 118 29 34 0.84 0.56-1.20 8 508 56 32 1.75 1.32-2.26 
 
MPA4 15 747 53 48 1.10 0.83-1.44 7 006 35 26 1.33 0.93-1.84 
 
Dydro-
gesterone  
7 702 12 9 1.33 0.69-2.33 591 2 1 4.81 0.58-17.4 
Other/mix
ed  
4 993 16 13 1.19 0.68-1.93 7 097 42 24 1.74 1.25-2.34 
All 45 560 110 104 1.06 0.87-1.26 23 202 135 83 1.63 1.36-1.91 
Transdermal 
NETA3 5 409 19 16 1.21 0.73-1.89 2 380 17 7 2.43 1.42-3.89 
 
1Classified according to the type of progestagen which was used first and at 5 years (no preregister use) 
2According to the type of progestagen which was used first and at 5 years (unknown preregister use possible) 
3Norethisterone acetate 
4Medroxyprogesterone acetate 
 
 
Case-control study (II)  
 
All forms of EPT use (< 5 years) of sequential, continuous or estradiol plus levonorgestrel 
releasing intrauterine device EPT showed a decreased risk for endometrial cancer (Table 18). 
The risk was smallest for women using estrogen and carrying levonorgestrel intrauterine 
device for 5-10 years (OR 0.16; 0.37-0.68). The highest risk (1.63; 1.12-2.38) was seen for 
the use of long-cycle EPT. The use of sequential EPT also carried an increased risk (1.38; 
1.15-1.66) after 10 years of use. In this group, the risk was highest for long-cycle EPT (2.95; 
2.40-3.62), and this risk significantly differed from that in women with sequential monthly 
EPT use. Tibolone was not accompanied with any changes in the risk for endometrial cancer. 
Mixed use of various hormones associated with an increased risk after 5 years of use (1.65; 
1.36-2.00), and the risk doubled after 10+ years of use (3.28; 2.92-3.68) (Table18). 
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Table 18. Odd ratios (OR) of endometrial cancer for the use of estradiol-progestagen 
therapy by estimated duration
1 
and mode of regimen (case-control study II). 
Mode of EPT and duration of 
use (years) 
Cases Controls OR
2
 95% CI p-value 
Sequential EPT      
<5 101 327 0.67 0.52-0.86 0.001 
5-10 127 337 1.11 0.87-1.41 0.396 
10+ 194 462 1.38 1.15-1.66 0.000 
Long-cycle EPT
3
      
<5 23 40 1.40 0.82-2.38 0.216 
5-10 61 99 1.63 1.12-2.38 0.011 
10+  204 228 2.95 2.40-3.62 0.000 
Continuous EPT      
<5 20 102 0.45 0.27-0.73 0.001 
5-10 28 157 0.57 0.37-0.88 0.011 
10+ 79 326 0.79 0.61-1.02 0.080 
Continuous estradiol 
 plus LNG-IUS
4
 
     
<5 7 45 0.39 0.17-0.88 0.023 
5-10 2 35 0.16 0.37-0.68 0.013 
10+ 7 16 1.70 0.63-4.53 0.287 
Tibolone      
<5 12 27 0.92 0.46-1.86 0.824 
5-10 4 8 1.47 0.38-5.69 0.571 
10+ 3 11 0.85 0.23-3.07 0.803 
Mixed therapy
5
      
<5 139 290 1.10 0.87-1.38 0.424 
5-10 257 409 1.65 1.36-2.00 0.000 
10+ 776 802 3.28 2.92-3.68 0.000 
1For those whose HT use initiated before the HT registration started (1994) the duration was estimated on the 
basis of age at last HT purchase and mode of regimen used during 1994-2007. 
2Reference category is never users of HT. OR adjusted for age, parity, age at first and last birth. 3Estradiol with 
oral progestagen courses of 10-14 days with 2-3 months intervals.  
4Levonorgestrel releasing intrauterine system.  
5Mixture of estradiol-only, progestagen-only, estradiol-progestagen therapy, or tibolone. 
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Uterine sarcoma (Study III) 
 
A total of 76 women with uterine sarcomas were encountered in the cohort study, of which 45 
(59%) had leiomyosarcomas, 24 (32%) stromal and 7 (9%) other sarcomas. The exposure to 
EPT for less than 5 years did not affect the risk for uterine sarcomas. In contrast, the exposure 
to EPT for 5 years or longer was associated with an increased risk for uterine sarcomas (SIR 
2.02; 1.36-2.91), and the risk was highest for leiomyosarcoma (2.64; 1.56-4.17) (Table 19). 
The mode of EPT was not a factor, and sequential and continuous modes of EPT carried 
similar sarcoma risks. 
 
 
Table 19. Number of uterine sarcoma cases (OBS) and expected cases (EXP) in women 
aged >50 years using estradiol-progestagen therapy 1994-2008 (N) and Standardised 
Incidence Ratios (SIR) with 95% confidence intervals (CI), by duration of use.  
Type of sarcoma / 
Duration 
N OBS EXP SIR (95% CI) 
 
Leiomyosarcoma 
     
≥6 months <5 years1 91 128 11 8.39 1.31 0.65-2.34 
 5 -10 y2 84 965 18 6.82 2.64 1.56-4.17 
 10 y or more2 31 473 5 1.26 3.98 1.29-9.28 
 Total 243 857 45 25.44 1.77 1.29-2.36 
 
Stromal sarcoma 
     
≥6 months <5 years1 91 128 6 6.16 0.97 0.36-2.12 
 5-10 y2 84 965 10 5.21 1.91 0.92-3.53 
 10 y or more2 31 473 2 0.96 2.08 0.25-7.51 
 Total 243 857 24 17.02 1.41 0.90–2.09 
 
All uterine sarcoma 
     
≥6 months <5 years1 91 128 18 16.13 1.12 0.66-1.76 
 5-10 y2 84 965 29 14.33 2.02 1.36-2.91 
 10 y or more2 31 473 8 2.66 3.01 1.30-5.93 
 Total 243 857 76 49.10 1.55 1.22-1.93 
 
1Data from the group with completely known estradiol-progestagen therapy  
2Registered estradiol-progestagen use since 1994 (unknown preregister use possible before 1994) 
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Cervical precancerous and cancerous lesions (IV) 
 
Altogether, 210 women with cervical squamous lesions (178 precancerous and 32 cancers) 
and 79 cervical glandular lesions (14 precancerous and 65 adenocarcinomas) were detected in 
the EPT cohort during 1994-2008. The incidence of precancerous lesions was not affected by 
the ever use of EPT, but the risk for squamous cell carcinoma was decreased (0.41; 0.28-0.58) 
and that for adenocarcinomas was increased (1.31; 1.01-1.67). These risk changes became 
more profound after exposure of longer than 5 years (Figure 10). However, the trend tests for 
squamous cell carcinoma and adenocarcinoma by exposure time was not significant when 
tested separately. The trends were significantly different (p = 0.003) when combined data of 
these cancers were tested (Figure 10). Different modes of EPT were not factors for cancer 
risk, but among users of continuous EPT, cervical adenocarcinomas were more often detected 
at the restricted stage (SIR 6.52; 1.78-16.69). In contrast, long-cycle EPT users were more 
often detected in the advanced stage of the disease (SIR 7.02; 2.28-16.39) compared to the 
background population. 
 
 
Figure 10. Standardized incidence ratio for cervical squamous cell carcinoma and 
adenocarcinoma in the users of estradiol-progestagen therapy, as expressed against the 
exposure time and any use. 
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DISCUSSION 
 
A major concern about the use of postmenopausal HT is the risk for cancer. This has been 
most conspicuous for breast cancer (Santen et al 2010), but it also concerns the hormone 
sensitive uterine malignancies that form approximately 7% of all cancers and over 60% of all 
female genital organ cancers in Finland (Finnish Cancer Registry 2011). The use of 
postmenopausal hormone therapy is popular, since approximately 40% of postmenopausal 
women use it for at least 6 months, as seen in a national evaluation of breast cancer (Lyytinen 
2009). It is also noteworthy that large post-war, baby-boom populations are now between 55-
65 years of age (Figure 11), and indeed, the incidence of endometrial cancer is predicted to 
increase by 29% to 2020 (Finnish Cancer Registry 2009). Furthermore, the mode of EPT 
regimens and the route of administration may be factors for uterine malignancy occurrence in 
hormone users, which calls for comparative studies on this aspect. I conducted four national 
studies on the impact of hormone therapy as the risk factor for uterine cancers. A national 
character of my study was judged to be important, because the way of using hormonal 
therapies, genetic background, nutrition and lifestyle, which may well be determinants for 
cancer related effects of hormone therapy, differ from one country to another and may well 
modify the possible impact of hormone therapy on the risk for cancer.  
 
 
Figure 11. Population pyramid of Finland 2009 (Engholm et al 2011). 
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Endometrial cancer 
 
The most popular EPT in Finland, monthly sequential regimen, associated with a 69% rise in 
the risk for endometrial cancer after 5 years of use in the cohort study. The higher risk in the 
cohort than case-control study derives probably from the fact that women classified as users 
for 5+ years may have used EPT years before the registry’s opening in 1994. A clear 
dependence between exposure duration and the risk for endometrial cancer was seen in both 
study settings; the risk increased by 156% in the cohort study after 10 years. Many 
observational studies show similar risk increases (Beresford et al 1997, Weiderpass et al 
1999, Doherty et al 2007, Lacey et al 2005), but not all (Voight et al 1991, Pike et al 1997, 
Beral et al 2005, Lacey et al 2007, Ravazi et al 2010). The main problem in many 
observational studies is the large variation in the duration of progestagen use and also the 
small number of endometrial cancer cases. Randomized control studies do not exist on 
sequential regimens and the current statement of the Endocrine Society Scientific concludes 
that “sequential EPT reduces the risk compared to estrogen but not as effectively as 
continuous EPT” (Santen et al 2010). It was also of interest that endometrial cancers in 
monthly sequential EPT users tended to be detected more often in a localized phase than in 
the background population is in line with earlier knowledge (Weiss et al 2006). My data 
cannot tell if this feature is a reflection of a possible diagnosis bias or a more malignant 
character of cancer in non-users. The proportion of type II endometrial cancer in my study 
was only 3%, which is small compared to the 10-20% presented in the literature (Acharya et 
al 2005, Amant et al 2005). 
 
The long-cycle sequential EPT was commonly used at the time of the cohort collection and 
especially before the registry’s opening in 1994. This regimen in both study settings showed 
an increased (63 % in the case-control study and 276 % in the cohort) risk for endometrial 
cancer after 5 years of use; the risk rose further up to 3-6-fold with 10+ years of use. The 
difference in the risk between these two studies can be explained by two facts. First, in the 
cohort study, more women with longer than 10 years exposure to EPT were included. Second, 
in the case-control study, women who may have used EPT only before the registry’s opening 
in 1994 might have been classified as controls, which may have decreased the risk.  
 
The Finnish observational study has concluded that the long-cycle EPT carries a 1.5-fold risk 
for endometrial cancer than monthly cycle EPT (Pukkala et al 2000). Most typical 
endometrial cancer, endometrioid adenocarcinoma, is developed through endometrial 
premalignant changes. A randomized, prospective 4-year study from Sweden reported a 
significantly higher annual incidence of endometrial hyperplastic changes (5.6% vs 1%) 
among the long-cycle sequential EPT users compared to the monthly sequential EPT users 
(Bjarnason et al 1999). Fortunately, the use of long-cycle sequential EPT has lost in 
popularity. Only 2 % of EPT users had been exposed to it in “fresh user“ subgroup in my 
cohort study. 
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In the cohort study, the continuous combined EPT was associated with a reduction (76%) in 
the risk for endometrial cancer already after 3 years of use, and in the case-control study the 
risk reduction (61%) was of the same magnitude. Some observational studies have found no 
changes in the risk for endometrial cancer in users of continuous combined EPT (Pike et al 
1997, Lacey et al 2005, Ravazi et al 2010), whereas the majority of the previous data are in 
line with my findings (Weiderpass et al 1999, Hill et al 2000, Lacey et al 2007, Doherty et al 
2007). Data from the UK also showed a decreased risk (0.71; 0.56-0.90), and the protection 
was noted as being highest in obese women (Beral et al 2005, Crosbie et al 2010). An 
overweight condition is present in almost 50% of endometrial cancer cases (Amant et al 2005) 
and it is unfortunate that in my studies this information was not available. In a randomized, 
placebo-controlled WHI trial, only a trend for reduced risk for endometrial cancer was seen 
(hazard ratio 0.81; 0.48-1.36) (Andersson et al 2003).There are several explanations for 
lacking significance for endometrial cancer risk in the WHI study: the population also 
included women who were originally randomized to the ET-only group; during the follow-up 
simplex hyperplasia patients were treated with 20 mg/day of MPA; the mean age of the 
women at recruitment in WHI study was 63; a majority (70%) of the women had overweight; 
and follow-up time was only 5.6 years, which may be too short time for developing 
endometrial cancer. 
 
In the case-control study, only 16 women with endometrial cancer were encountered in the 
continuous estradiol plus LNG-IUS group, but yet, the risk was reduced by 84% if the 
exposure was 5-10 years. These data are novel: no previous data exist on endometrial cancer 
as a primary endpoint with such a long follow-up in users of the estradiol plus LNG-IUS 
combination. However, this finding may be expected in view of the data that a short-term use 
of the combination of LNG-IUS and estrogen did not cause proliferative or hyperplasic 
endometrial changes (Suvanto-Luukkonen and Kauppila 1999, Varila et al 2001, Hampton et 
al 2005). The levonorgestrel intrauterine device system also wins a place as a treatment for 
endometrial hyperplasia because it has shown full endometrial regression in hyperplasia of all 
types (see for a review Varma et al 2006, Leslie 2012). 
 
Only 19 tibolone users were diagnosed with endometrial cancer cases in the case-control 
study, but the risk was similar as it was in the controls. The endometrial effects of tibolone 
have been conflicting in previous studies; observational studies have shown increased risks 
for endometrial cancer (de Vries et al 2005, Beral et al 2005), but three other studies 
comparing tibolone to continuous combined EPT or placebo for 3 years found no difference 
in endometrial safety (Langer et al 2006, Archer et al 2007, Ettinger et al 2008). My result 
supports the findings from randomized trials and agrees with the Endocrine Society Scientific 
Statement, which concludes that tibolone does not induce endometrial hyperplasia or cancer 
(Santen et al 2010).  
 
Transdermal HT has won popularity, perhaps due to the presumed vascular safety and 
decreased risk for thromboembolism (Straczek et al 2005, L’Hermite et al 2008, Utian et al 
2010). Transdermal estradiol administration may also be accompanied with positive vascular 
effects, particularly in women with vasomotor symptoms (Tuomikoski et al 2009). The route 
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of estrogen administration may not be a factor for breast cancer risk (Fournier et al 2007, 
Lyytinen 2009). I could not compare the route of administration of sole estrogen, because 
women using ET-only with an intact uterus were not included. In contrast, sequential therapy 
with NETA containing EPT for more than 5 years was accompanied with a 75% increased 
risk if given orally and 143% risk elevation if given transdermally, but these risks did not 
differ significantly from each other. Data on the trandermal use of HT and endometrial 
protection are sparse, but fully transdermal sequential and continuous EPT (estradiol 50 
μg/day with NETA 170 μg/day) have shown adequate endometrial protection in a two-year 
study (Ylikorkala and Rozenberg 2000). Trandermal use of HT may be superior to oral use in 
regard to vascular health (Tuomikoski 2010). My data implying endometrial safety for 
transdermal EPT may give additional support to favour a transdermal route of EPT 
administration.  
 
Use of different progestagens as part of EPT regimens varies from one country to another 
(Campagnoli et al 2005). I could compare in both cohort and case-control studies the three 
most common progestagens in Finland; norethisterone acetate (44%), medroxyprogesterone 
acetate (27%) and dydrogesterone (12%) in monthly sequential EPT. These progestagens 
showed similar endometrial effects when used concomitantly with estradiol. These new 
findings demonstrate that another factor than endometrial safety should be decisive when an 
EPT regimen is being selected.  
 
Uterine sarcoma 
 
Because of the rarity of uterine sarcomas, the data are sparse on the risk factors. Previously, 
early menarche, uses of oral contraceptives and high body mass index have shown to increase 
the risk for uterine sarcomas (Schwartz et al 1991, Schwartz et al 1995). Tamoxifen use has 
been associated to an increased risk for uterine sarcomas and particularly with 
carcinosarcomas (Wickerham et al 2002), that are no longer classified as mesencymal tumors 
(Mutch et al 2009). I did not include carcinosarcomas as uterine sarcomas. Women with a 
history of breast or any other cancer were not excluded, but these women seldom use EPT, 
and therefore such women were likely to be excluded from the EPT user cohorts. Estrogen 
stimulates cell proliferation, differentiation and suppresses apoptosis in endometrial cancer 
(Kaaks et al 2002), and by sharing the same hormone related epidemiological risk factors, it is 
likely that estrogen is also involved in mesenchymal tumor growth. Progesterone stimulates 
mitotic activity of the uterine smooth muscle and it may also act as a risk factor for uterine 
sarcomas. As a whole, EPT with estrogenic and progestagenic components may well be a 
factor for the genesis of uterine sarcoma. 
 
According to my knowledge, my study is the first one to assess EPT use as a risk factor for 
uterine sarcomas. The risk for sarcoma was increased 2-fold for uterine sarcomas after 5 years 
of use, and the risk increased to 3-fold after 10 years of use. The risks were higher for 
leiomyosarcoma (164%) compared to endometrial stromal sarcoma (91%) after 5 years of use. 
My data confirm the hormone-sensitive character of uterine sarcomas, and indeed, a majority 
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express receptors for estrogen and progesterone. Interestingly, ER- and PR-positive 
leiomyosarcoma patients have shown better disease-specific survival rates than receptor 
negative patients (Koivisto-Korander et al 2010), maybe due to a higher state of 
differentiation. Even though my study was nationwide, only 76 cases of uterine sarcomas 
were encountered in the EPT cohort, and this reduced the statistical power of my data.  
 
The use of postmenopausal HT is contraindicated for women operated for hormone-sensitive 
endometrial stromal sarcoma because ET and tamoxifen postoperatively have been associated 
with an increased recurrence risk (Reich et al 1999, Chu et al 2003, Pink et al 2005).  
 
Cervical cancer 
 
Hormone therapy is predominantly used in countries with a low incidence of cervical cancer. 
Therefore, my nationwide data on the possible associations between cervical 
(pre)malignancies and EPT use are to a large extent novel and therefore important, even 
though the data for confounding factors like smoking and HPV infection status could not be 
controlled. It is known that the HPV infection may reactivate in the first menopausal years 
(Burchell et al 2006, Yasmeen et al 2006).  
 
I could not find any association between the use of EPT and precancerous lesions in 
squamous or glandular epithelium of the uterine cervix. Nevertheless, the use of EPT was 
associated with a decreased risk (66%) for squamous cell carcinoma and an increased risk 
(83%) for cervical adenocarcinoma after 5 years of use. The increased risk for cervical 
adenocarcinoma showed a tendency for exposure-duration dependency of EPT use. These 
results imply that the use of EPT may arrest a progression of a CIN lesion to squamous 
cancer, whereas the genesis of adenocarcinoma originating from hormone sensitive glandular 
cells may be stimulated by the use of EPT. It is established that Pap smears detect 
precancerous lesions of squamous cell carcinoma more accurately than those of cervical 
adenocarcinoma (Dahlström et al 2010). Thus, differences in the frequency of Pap smear 
collection may lead to a bias; the users of EPT more frequently visit gynecologists and 
undergo Pap smear sampling. Therefore, squamous precancerous changes are treated before 
turning into cancer.  
 
Two randomized trials have failed to show the impact of EPT on the risk for HPV infection or 
cervical cancer (International Agency for Research on Cancer 2005). Continuous combined 
EPT (CEE/MPA) did not associate with any alternation in the occurrence of premalignant or 
malignant cervical cell changes (Sawaya et al 2000, Yasmeen et al 2006). My results of a 
decreased risk for squamous cell carcinoma in Finnish EPT users are in line with an earlier 
study assessing users of EPT (Lacey et al 2000). Estrogen-only therapy users have also shown 
a decreased risk for cervical cancer (Parazzini et al 1997). My study is the first one showing a 
significantly increased risk for cervical adenocarcinoma in EPT users, but a similar trend was 
seen before in a case-control study comprising 13 cases (OR 2.1, 95% CI 0.95-4.6) (Lacey et 
al 2000). 
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Study strengths and limitations 
 
Before drawing any conclusions about the clinical value of my data, study strengths and 
limitation need to be addressed. I had detailed and reliable information about HT preparations 
used, exposure times, mode of regimens and routes of administration from the Medical 
Reimbursement Registry since 1994. In many previous epidemiological studies, these data are 
mostly collected by telephone interviews or in mailed questionnaires (Weiderpass et al 1999, 
Beral et al 2005, Doherty et al 2007, Ravazi et al 2010). This can lead to recall bias: women 
with a diagnosed cancer are more likely to recall the use of HT than women without cancer; 
this bias was not present in my study. The coverage of the purchase data is complete due to 
automatic registration with the reimbursement registry at pharmacy. Hormone therapy 
regimens are only partly reimbursed (42%), and therefore the women likely used the regimens 
they had bought with their own money. In Finland, the mean natural menopausal age is 51 
years (Luoto et al 1994), and therefore the threshold limit of 50 years for inclusion was 
reasonable.  
 
The use of the Medical Reimbursement Registry and the Finnish Cancer Registry enabled 
me to perform the nationwide study and to gain information about uterine cancers with 
different histological types. The data on cervical precancerous lesions strengthened my study, 
even though the number of CIN grade 3 lesions may be underestimated due to insufficient 
compliance for reporting. Hysterectomized women were excluded from the risk analyses, 
because women without a uterus are no longer at risk for uterine cancers. The data on 
hysterectomy from the Hospital Inpatient Register of the National Institute of Health and 
Welfare are reliable (Keskimäki et al 1994). 
 
The limitation of the cohort studies is the fact that HT users were compared with the entire 
background population (also including HT users), which may dilute the risk estimates 
slightly. Additionally, the background population included hysterectomized women. In 
Finland, the hysterectomy rate has been high (approximately 20% of women by the age of 60) 
(Vuorma et al 1998), but this rate has declined by 34% during the last decade (Brummer et al 
2009). It has been approximated that in Finland, the hysterectomy-corrected age-adjusted 
incidences for endometrial and cervical cancers would be 29% and 11% higher than 
uncorrected rates (Luoto et al 2004).  
 
Exposure data about HT purchases are from 1994 onwards, and the possible use of HT 
before 1994 is unknown. This limitation was handled by dividing the cohort to two sub-
groups according to the HT initiation. This allowed me to separate the long-term EPT users 
from the short-term users, whose exposure was completely known. In the case-control study, 
the initiation of HT was estimated at the age of 52 in women whose use of EPT had started 
before 1994. Those women who may have used HT only before 1994 were misclassified as 
non-users because of the lack of HT use information. This shortcoming may dilute risk 
estimates towards unity in the case-control study. Additional limitation in these studies is the 
lack of risk analyses of vaginal estrogen regimens. Vaginally administrated estrogens have 
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previously shown no/weak association with endometrial cancer (Weiderpass et al 1999, 
Epstein et al 2009). It is, however, noteworthy that those vaginal estrogen treatments, also 
available over the counter without prescription, most often contain estriol, which is the 
weakest estrogen and often classified as a metabolite of all estrogens. Therefore, it sounds 
questionable if such agents would prove to be factors for uterine malignancies.  
 
In the cohort studies, I could not control our data for confounding factors such as parity, 
weight, age at menarche, age at first and last birth, age at menopause, contraceptive pill use, 
tamoxifen use, smoking, socioeconomic level or HPV status. Finnish users and nonusers of 
postmenopausal hormone therapy do not appear to differ socioeconomically (Topo et al 
1999); a recent study from eastern Finland showed rather similar HT prescription rates in 
women with the lowest and the highest educational levels (47.9% vs 61.8%), even though 
self-reporting of HT use was increased among women with a higher educational level 
(Sandini et al 2008). Furthermore, a previous association between the incidence of 
endometrial cancer and social class disappeared already in the early 1980s (Pukkala and 
Weiderpass 1999). Therefore, I feel that confounding factors between HT users and 
background population would not explain the differences in the uterine cancer risks between 
the users and nonusers of hormone therapy, even though results were not adjusted for 
important uterine cancer co-factors like obesity, diabetes mellitus, smoking and 
socioeconomic status. In the case-control study I could control the parity and age at last birth, 
which are known confounders for endometrial cancer (Hinkula et al 2002, Bray et al 2005, 
Chubak et al 2005), and basically, the findings in the cohort and case-control studies did not 
differ. 
 
The fact that women using HT visit gynaecologists more often than non-users, may lead to 
diagnosis bias. This may be supported by my findings that endometrial cancer was more 
often encountered in a local stage in hormone users. However, endometrial cancers and 
uterine sarcomas frequently cause bleeding disturbances and other symptoms, and therefore 
these malignancies would likely have been diagnosed sooner or later in spite of routine visits 
to the physician. The Finnish organized screening system for cervical cancer, offered free of 
charge to all women, diminishes the diagnosis bias. 
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Clinical implications 
 
Postmenopausal HT use is indicated to treat vasomotor and other symptoms that reduce the 
quality of life (Finnish Consensus Statement 2004). Immediate vasomotor symptoms and 
subsequent urogenital atrophy are alleviated most efficiently with HT (Table 8). The risks of 
HT must be considered individually. Several pre-existing health risks such as obesity, 
diabetes, smoking, and family history of thromboembolism, or breast/endometrial cancer 
should be considered before initiating postmenopausal HT (Tables 10 and 11). The changes in 
the risk for uterine malignancies I observed in Finnish hormone users should be taken into 
account when a physician sees postmenopausal women considering the use of hormone 
therapy. 
 
From the endometrial point of view, the continuous combined EPT regimens associate with 
an reduced endometrial cancer risk, sequential EPT carries a mild to modest risk after 5-10 
years of exposure, and long-cycle regimens have the highest risk for endometrial cancer 
already after short-term use. The most common progestagens in Finland (NETA, MPA and 
dydrogesterone) carried similar endometrial effects, and transdermal routes of administration 
did not differ from oral administration in the risk for endometrial cancer. Absolute risk 
changes for endometrial cancer and the use of EPT for 10,000 women who would be followed 
up for 10 years (100,000 women years) would mean 30-40 fewer cases in continuous EPT 
users and 80 extra cases in sequential EPT users. 
 
The association of EPT use and increased risk for uterine sarcoma is a novel finding. Even 
though it is an important discovery, it has limited clinical significance because the number of 
uterine sarcomas is small. The absolute risk increase among 10,000 long-term EPT users 
followed for 10 years would mean 2-3 extra uterine sarcoma cases. 
 
An important finding for HT users and clinicians is the opposite association of EPT use and 
cervical cancer according to the histological type. The fact that EPT use may increase the risk 
for cervical adenocarcinoma should alert clinicians if any bleeding symptoms occur in 
postmenopausal women. Absolute risks of using EPT for 5+ years for 10,000 women during 
10 years of follow-up (100,000 women years) would mean 2-3 fewer squamous cell 
carcinoma and 2 extra adenocarcinoma cases. 
 
Even though postmenopausal HT is classified as carcinogenic to humans (International 
Agency for Research on Cancer 2007), it is controversial whether HT actually induces a new 
cancer case or could it just stimulate the tumor growth of a pre-existing cancer. My 
epidemiological studies show associations of possible carcinogenic factors (EPT) and 
incidence changes of uterine malignancies, and causality cannot be proved. In endometrial 
cancer, ET only has clearly increased endometrial proliferation, which increases the risk for 
errors in transcription (Yeh 2007), and this proliferation is opposed more or less with 
progestagen (Stanzyk 2003). In cervical adenocarcinoma and uterine sarcoma, the mechanism 
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is not that clear; they may also be affected by genotoxic by-products of estrogen metabolism 
as is the case in breast cancer (Deroo and Korach 2006). 
 
My studies may stimulate further studies. Estrogen-progestagen therapy increases the risk for 
breast cancer more than the sole use of estrogen (Cogliano et al 2005, Lyytinen et al 2009). 
Resent data from WHI showed even decreased risk for breast cancer in women using ET only 
(Anderson et al 2012). It is estimated that every 10 cases of endometrial cancers prevented by 
adding progestagen to estrogen over 10 years, it would cause 14 extra cases of breast cancers 
compared to the sole use of estrogen (Beral et al 2003). Therefore, it has presently been 
proposed that a sole estrogen at low / ultra-low dosages could also be prescribed to non-
hysterectomized women if endometrial surveillance (ultrasound, biopsies) is strictly provided 
(Collins 2006, Utian et al 2010). Such an option should be studied in proper trials. Obviously, 
there is a need for further options to prevent endometrial proliferation, and the combination of 
SERM to estrogens may be one possibility (Kharode et al 2008, Lobo et al 2009), but this 
approach also needs confirmation. Transdermal use of estrogen and LNG-IUS may win 
popularity due to its more positive vascular effects and decreased endometrial risks, and 
benefits of these regimens should be assessed in future observational and randomized trials. 
Hormone receptor status of the tumors seems to be an important determinant for uterine 
sarcomas (Akhan et al 2005, Koivisto-Korander et al 2010). The use of HT may favor the 
occurrence of more benign forms of endometrial cancer (Weiss et al 2006). To address these 
questions, mortality studies on patients with uterine cancer with and without preceding 
hormone therapy is warranted.  
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CONCLUSIONS 
 
The following conclusions can be drawn on the basis of my thesis  
 
1. The use of continuous EPT associates with a decreased risk for endometrial cancer 
already after 3 years of use. Oral continuous use of EPT or estradiol with a 
levonorgestrel releasing intrauterine system for 5-10 years is associated with a 
decreased risk for endometrial cancer.  
 
2. The use of sequential EPT < 5 years does not affect the risk for endometrial cancer. 
The use of sequential EPT ≥ 10 years associated with an increased risk (38-156%), 
and the risk showed exposure-time dependency. Oral and transdermal routes of 
administration carried similar risks. Sequential NETA, MPA and dydrogesterone as 
parts of EPT did not differ in endometrial safety.  
 
3. The use of long-cycle sequential EPT even for < 5 years associated with an increased 
risk for endometrial cancer. The risk increased by 2-3 fold with 5-10 years of use and 
3-6 fold when the exposure time reached 10 years. 
 
4. The incidence of cervical precancerous lesions was not affected by the use of EPT, but 
the risk for squamous cell carcinoma was decreased (66%) and the risk for 
adenocarcinoma was increased (83%) after 5 years of use. 
 
5. The use of EPT for 5 years or more associated with an increased risk for uterine 
sarcoma, and the risk was highest for leiomyosarcoma. The risk was not affected by 
the mode of EPT. 
 
6. My data are important elements in information for women using or considering the 
initiation of postmenopausal hormone therapy.  
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